Most vaginally inserted methods have limited availability and use despite offering characteristics that align with many women’s stated preferences (e.g., nonhormonal and/or on demand). The objective of this review was to identify enablers and barriers to women’s adoption and continuation of vaginally inserted contraceptive methods in low- and middle-income countries (LMICs). We searched three databases (PubMed, Embase, and Web of Science) and 18 websites using keywords related to five vaginally inserted contraceptive methods (diaphragm, vaginal ring, female condom, copper intrauterine device [IUD], hormonal IUD) and terms associated with their adoption and continuation. Searches were limited to resources published between January 2010 and September 2020. Studies eligible for inclusion in our review presented results on women’s use and perspectives on the enablers and barriers to adoption and continuation of the vaginally inserted contraceptive methods of interest in LMICs. Relevant studies among women’s partners were also included, but not those of providers or other stakeholders. Data were coded, analyzed, and disaggregated according to a framework grounded in family planning (FP) literature and behavioral theories common to FP research and program implementation. Our initial search yielded 13,848 results, with 182 studies ultimately included in the analysis. Across methods, we found common enablers for method adoption, including quality contraceptive counseling as well as alignment between a woman’s preferences and a method’s duration of use and side effect profile. Common barriers included a lack of familiarity with the methods and product cost. Notably, vaginal insertion was not a major barrier to adoption in the literature reviewed. Vaginally inserted methods of contraception have the potential to fill a gap in method offerings and expand choice. Programmatic actions should address key barriers and enable voluntary use.

INTRODUCTION

In low- and middle-income countries (LMICs), 218 million women are estimated to have an unmet need for voluntary family planning (FP), and nearly half (49 percent) of pregnancies
are unintended (Sully et al. 2020). As a result of unintended pregnancies, some women and their families experience severe social, economic, and health consequences (Singh, Sedgh, and Hussain 2010). Women cite a number of reasons for not using contraception despite wanting to avoid unintended pregnancy: concerns about side effects and health risks; infrequent sex; opposition to contraception; and breastfeeding and/or delayed menstruation postbirth (Sedgh, Ashford, and Hussain 2016). For some, these reasons for nonuse of contraception may reflect misconceptions, stigma, social norms, or other factors, while for others, these reasons may reflect a lack of access to methods that suit their needs and preferences.

Expanded access to a wide range of modern contraceptive methods is well-established as a global health priority, recognizing that diverse options are needed to meet women’s varying contraceptive needs and preferences (WHO 2014). Despite efforts to broaden options, only two or three methods account for most contraceptive use in LMICs. The predominant methods vary by country but include male condoms, oral contraceptives, injectables, implants, copper intrauterine devices (IUDs), female sterilization, and traditional methods such as withdrawal. Although the use of traditional methods has declined over the past decade, these less effective methods represent, on average, 17 percent of the method mix across 113 LMICs. Vaginally inserted contraceptives, which refer to methods that are inserted into the vagina or uterus by the user or a trained provider—such as female condoms, diaphragms, vaginal rings and hormonal IUDs—have limited availability and are used less frequently. An exception is the copper IUD. Copper IUD use is high in some countries but very low in others, including LMICs in sub-Saharan Africa (Bertrand et al. 2020). Until recently, the levonorgestrel (LNG)-releasing IUD (also known as the hormonal IUD, hormonal intrauterine system (IUS) or LNG-IUS) was only available through the private sector in many LMICs. Based on the promising results of several pilot introductions in sub-Saharan Africa, the United States Agency for International Development (USAID) and the United Nations Population Fund (UNFPA) added the hormonal IUD to their procurement catalogs in June 2021, which will facilitate broader access to this method in the future (FP2020 2021).

Research suggests that there may be a market for vaginally inserted contraceptive methods, especially since these options offer benefits that align with the stated preferences of women who have an unmet need for contraception. In LMICs, the most common reasons women cite for nonuse of contraceptives are “health concerns,” which include health risks,
fear of side effects, interference with menstruation and other bodily processes, and “infrequent sex” (Moreira et al. 2019). Many women also say they want more nonhormonal contraceptive choices and methods with milder or no side effects (Hemmerling, Christopher, and Holt 2020). Others want more “on demand” options that can be used only when needed rather than continuously (Raymond et al. 2014). Diaphragms and female condoms, for example, have minimal side effects (e.g., irritation for a minority of users) and can be used on demand. These two methods, along with the contraceptive vaginal ring, are also woman-controlled self-care options, and two of them (rings and diaphragms) are typically undetectable by the male partner during sex (Novák et al. 2003; Sahin-Hodoglugil et al. 2011). Copper and hormonal IUDs must be inserted by a provider and have some side effects; however, the copper IUD has no hormone-related side effects or contraindications, and the hormonal IUD may have less pronounced side effects than other hormonal contraceptives because of its localized release of hormones in the uterus and lower levels of systemic exposure to these hormones (Reinecke et al. 2018). Vaginal rings may also have some side effects, but similar to the hormonal IUD, they expose users to lower levels of hormones than other methods (van den Heuvel et al. 2005).

Supply- and demand-side factors have limited the market for vaginally inserted contraceptives to date. Regulatory approvals, product costs, the need for provider training, supply chain management challenges, and policies influence product availability. Some reproductive health experts argue that demand for self-inserted vaginal methods is diminished by reluctance, discomfort, embarrassment, or cultural proscriptions related to women touching their genitals, while others assert that low acceptability is a myth contradicted by the evidence base (Latka 2001; Gollub 2000; Peters, Jansen, and van Driel 2010; RamaRao et al. 2018; Roy et al. 2020). With more vaginally inserted contraceptive options under development, including multipurpose prevention technologies (MPTs) such as a vaginal ring that prevents HIV and unintended pregnancy (Bashi et al. 2019), it is important to understand supply- and demand-side factors that could inhibit or facilitate the use of vaginal methods.

This review was conducted to better understand the demand-side factors influencing the market in LMICs for vaginally inserted contraceptives. Past studies and literature reviews have focused on specific contraceptive methods (Mishra et al. 2017; Vargas et al. 2019; Gallo, Kilbourne-Brook, and Coffey 2012) or long-acting reversible contraceptives (LARCs; Coles and Shubkin 2018), but none have examined vaginally inserted methods as a category.

Specifically, this paper aims to (1) identify enablers and barriers to the adoption and continuation of vaginally inserted methods of contraception and (2) discuss opportunities for FP implementers to adjust programs in response to the enablers and barriers identified through this literature review.

Description of Vaginally Inserted Methods Reviewed

Table 1 presents the vaginally inserted contraceptive methods covered in this paper. It is important to note that the scope of the review included MPTs, such as female condoms, that offer protection from HIV as well as unintended pregnancy. However, the review excluded HIV prevention products that do not prevent unintended pregnancy. Even so, the results may be
### TABLE 1  Vaginally inserted contraceptive methods included in this literature review

| Method                        | Description                                                                                           |
|-------------------------------|--------------------------------------------------------------------------------------------------------|
| Female condoms (also known as internal condoms) | Users insert this barrier method to prevent unintended pregnancy and sexually transmitted infections (STIs), including HIV, during vaginal sex. The method works by preventing bodily fluids from entering the wearer’s body. Although internal condoms can also be used inside the anus to protect against STIs, this literature review focused on vaginal insertion. As of 2021, four manufacturers offer female condoms that have been prequalified by the World Health Organization (WHO):  
• Cupid® from Cupid Ltd.  
• FC2® (which replaced the earlier-generation FC®) from The Female Health Company  
• Woman’s Condom from Shanghai Dahua Medical Apparatus Co. Ltd.  
• Velvet from HLL LifeCare Ltd. |
| Diaphragm                     | Users insert this barrier method before sex and remove it six or more hours after sex. The product is a thin contraceptive cup that fits over the cervix to prevent sperm from entering the uterus. Contraceptive gel or spermicide is typically used with diaphragms. As of 2021, two manufacturers offered diaphragms with Stringent Regulatory Authority (SRA) approval:  
• Single-size SILCS, marketed as the Caya® contoured diaphragm, from Medintim  
• Milex® Wide Seal Omniflex (multiple sizes) from CooperSurgical  
The Ortho All-Flex Diaphragm from Janssen Pharmaceuticals Inc., was discontinued in 2013 (Cervical Barrier Advancement Society 2022). |
| Contraceptive vaginal ring    | Users insert this hormonal method into the vagina. Rings that contain progestin and estrogen work mainly by preventing ovulation. They should be worn by the user for three weeks, then removed for one week of each month, during which the client will experience a menstrual period. As of 2021, two manufacturers offer contraceptive vaginal rings with SRA approval:  
• NuvaRing® from Merck & Co. Inc. (one ring per menstrual cycle)  
• Anovora® from TherapeuticsMD Inc. (one ring per year)  
Breastfeeding women can use the progesterone vaginal ring Progering®, which is inserted in the vagina from four weeks postpartum for continuous use for up to three months. Progering® has been approved in a number of LMICs but does not yet have WHO prequalification or SRA approval. |
| Copper IUD                    | Providers insert this T-shaped copper device through the vagina into the woman’s uterus. The copper IUD works by creating a local inflammatory response, in addition to releasing copper that weakens sperm, to prevent sperm from reaching the fallopian tubes for fertilization (FHI 360 1995). Copper IUDs can be used for up to 10–12 years. The TCu380A IUD is the preferred IUD model for public sector procurement on the basis of its safety and efficacy, which is higher than that of prior generations of IUDs (WHO et al. 2011). The Paragard® TCu380A IUD, now owned by the Cooper Companies, has SRA approval (US FDA 2019). In addition, six manufacturers offer WHO prequalified TCu380A IUDs as of 2020 (UNFPA 2020). |
| Hormonal IUD                  | Providers insert this T-shaped device through the vagina into the woman’s uterus. The hormonal IUD releases a low, steady dose of progestin hormone directly into the uterus. Depending on the product, the hormonal IUD can be used for up to 5–7 years. As of 2021, two hormonal IUD products have SRA approval and are available in LMICs:  
• Avibela® from AbbVie and Impact RH360  
• Mirena® from Bayer AG  
The International Contraceptive Access Foundation also donates their unbranded hormonal IUD, the LNG-IUS, to LMICs. |
relevant to HIV prevention products that are inserted vaginally. Gels, spermicides and foams that are vaginally inserted were excluded from our review due to a lack of relevant literature.

The consumer price of each of the methods described varies based on what specific product is desired and/or available, whether the product is accessible through the public or private sector, and what additional user fees may be layered on top of the commodity (e.g., fees for insertion, including required supplies). For the products available through UNFPA—the female condom, copper and hormonal IUDs—the procurement prices are published online (UNFPA 2021). In the private sector, prices vary widely across and within countries, as documented by the FPwatch Project in select LMICs (PSI 2017).

MATERIALS AND METHODS

Search Strategy

Peer-Reviewed Literature

We searched three databases—PubMed, Embase and Web of Science—using a combination of keywords related to the vaginally inserted contraceptive methods of interest (diaphragm, vaginal ring, female condom, copper and hormonal IUDs) as well as terms associated with their adoption and continuation. (See Supporting Information for Search Terms.) The search was limited to literature published in English between January 2010 and September 2020, when the search was performed. Given recent improvements in several of the vaginally inserted contraceptive methods included in this review, we limited our search to the last 10 years to capture the most recent and relevant research.

Gray Literature

To supplement the peer-reviewed literature, we also conducted a manual search of 18 websites that were selected in consultation with subject matter experts. Websites were for organizations and repositories focused on contraceptive introduction, service provision, and research. (See Supporting Information for Gray Literature Websites.) We used a similar, but abbreviated, set of search terms to those used for the peer-reviewed literature. The search was limited to resources published online in English from January 2010 to September 2020, when the search was performed.

Inclusion and Exclusion Criteria

Eligible studies were those describing original research conducted in countries that met the definition of LMICs as defined by the World Bank (The World Bank 2021). Eligible studies focused on demand-side enablers and barriers for the adoption and continuation of the previously identified vaginally inserted methods of contraception. Studies about women’s FP use and perspectives on enablers and barriers for contraceptive use were included as well as relevant studies among women’s partners. No studies were included that focused solely on provider or other stakeholder perspectives. Studies were excluded if reported findings could not be attributed to one of the specific contraceptive methods of interest. Studies pertaining to the sole use of a method for HIV prevention or the treatment of gynecological disorders...
were excluded. Publications that did not present new data (e.g., commentaries, systematic reviews) were also excluded.

**Study Selection**

Duplicate references were removed from the initial list of peer-reviewed results. The title and abstract of the remaining results were screened independently by two different authors to determine relevance (DH, AD, or AR). Disagreements were resolved by review from a third author. The full text of the remaining references was then screened by two different authors for relevance (DH, AD, KM, or AR). Again, disagreements were resolved by review from a third author. For the remaining peer-reviewed results, one author (DH, AD, KM, or AR) extracted the relevant data using a template designed for this purpose in Microsoft Excel. Data extraction was then reviewed by a second author for accuracy (DH, AD, KM, or AR). For the gray literature, the full text of each result was screened independently by two authors for inclusion (DH, AD, KM, or AR), with disagreements being resolved by a third author. Data extraction for the gray literature was performed by one author, with review and input from a second author as needed (DH, AD or KM).

**Data Analysis**

Prior to analyzing the findings, we developed a framework grounded in the FP literature with a list of codes of enablers and barriers that influence contraceptive adoption and continuation. We identified demand-side enablers and barriers from behavioral theories commonly used in FP research and program implementation, including the Health Belief Model (Rosenstock 1974), Transtheoretical Model (LaMorte 2019), Social Cognitive Model (Bandura 1986), Integrative Model (Fishbein and Yzer 2003), and COM-B Model (The Decision Lab 2021). Following data extraction, individual findings were grouped by the contraceptive method in Microsoft Excel, and three authors iteratively refined the codes by testing them on a randomly selected sample of results. The authors then reviewed coding discrepancies together and with the larger group of authors, identified new emergent codes and agreed on a standardized set of definitions for codes to include in the framework. (See Supporting Information for the Code List.) The remaining results were then coded by three authors, with any new emerging codes presented to the larger group and definitions agreed upon by the group. The authors who completed the coding also conducted random spot checks on the other authors’ work to ensure continued agreement on the use of codes.

Following the coding, we tabulated the findings by contraceptive method type and code to identify important themes that were common across methods and unique to specific methods. The findings were further disaggregated to examine themes that were relevant as either barriers or enablers to the adoption or continuation of specific methods.

**RESULTS**

In total, our search of the peer-reviewed and gray literature yielded 13,848 results. After removing 4,908 duplicates, 8,940 unique results remained for screening by title and abstract. Following screening by title and abstract, 631 results were moved to full text review. In the
Barriers and Enablers to Use of Vaginally Inserted Contraceptive Methods

end, 182 studies met the inclusion criteria and were included in the analysis (Figure 1; see Supporting Information for the Included Studies).

Per the inclusion criteria, all studies included in our review were based on research in LMICs. More specifically, 54 percent of the included studies were from sub-Saharan Africa, 27 percent from Southeast Asia, 9 percent from East Asia and the Pacific, 5 percent from Latin America and the Caribbean, 3 percent from the Middle East and North Africa, and 1 percent were from countries in multiple regions.

The top 10 enablers and barriers to the adoption and continuation of three or more vaginally inserted methods of contraception are listed in Table 2.

Enablers

Counseling by a trained provider or community health worker was the most important enabling factor for women to adopt a vaginally inserted contraceptive method (McDonald-Mosley et al. 2010; Shapiro 2016; Vakilian et al. 2018; Harris and Angel 2020; Miller et al. 2018; Nanda et al. 2018; K. Thapa et al. 2019; Makins et al. 2018; Hayes and Kilbourne-Brook 2016a; Machado et al. 2013; Gottert et al. 2015; Shapiro et al. 2014; Wasim et al. 2018; Zafar et al. 2019; Eluwa et al. 2016; Karra et al. 2019; Somesh Kumar et al. 2014; Huber-Krum et al. 2019). According to the literature reviewed, effective counseling includes a provider reviewing a method’s advantages and disadvantages, including potential risks and side effects, and instructions on how to use the method correctly. For lesser-known self-care methods, such as the diaphragm and vaginal ring, providing demonstrations and giving women the
TABLE 2  Barriers and enablers to the adoption and continuation of vaginally inserted contraception

| Enablers                                                                 | Inserted by user | Inserted by provider |
|--------------------------------------------------------------------------|------------------|----------------------|
|                                                                          | Diaphragm        | Vaginal ring         | Female condom | Copper IUD | Hormonal IUD |
| Counseling by a trained provider or community health worker             | A                | A                    | A             | A          | A            |
| Duration of use                                                          | A, C             | A, C                 | A, C          | A, C       | A, C         |
| Acceptable side effect profile                                          | A                | A                    | A             | A          | A            |
| Nonhormonal method                                                       | A                | A                    | A             | A          | A            |
| Provides dual protection<sup>a</sup>                                      | A                | A                    | A             | A          | A            |
| Reversible method<sup>b</sup>                                             | A                | A                    | A             | A          | A            |
| Recommended by a friend, family member or health care provider           | A                | A                    | A             | A          | A            |
| Satisfaction with use                                                    | C                | C                    | C             | C          | C            |
| Partner sexual satisfaction                                              | C                | C                    | C             | C          | C            |
| Partner attitudes                                                        | A                | A                    | A             | A          | A            |
| Cost, including upfront/recurring costs and the cost of removal          | A                | A                    | A             | A          | A            |
| Partner attitudes                                                        | A                | A, C                 | A, C          | A, C       | A            |
| Concerns about insertion                                                 | A                | A                    | A             | A          | A            |
| Anticipated and experienced side effects                                  | A                | A                    | A             | A, C       | A, C         |
| Myths and misconceptions about products                                  | A                | A                    | A             | A          | A            |
| Concerns about product performance                                       | A                | A                    | A             | A          | A            |
| User sexual satisfaction                                                 | A                | A, C                 | C             | A, C       | C            |
| Partner sexual satisfaction                                              | A                | A, C                 | C             | C          | A            |
| Comfort and fit                                                          | C                | C                    | C             | C          | C            |

<sup>a</sup> The diaphragm and vaginal ring do not currently offer dual protection; however, several research studies included in our review assessed women’s potential interest in a multipurpose prevention technology (MPT) version of these methods (e.g., combining the diaphragm or vaginal ring with a microbicide). This accounts for the dual protection results presented for both methods.

<sup>b</sup> Other positive product attributes included acceptable to use while breastfeeding, immediate return to fertility, product design (color, material), and interest in trying a new product.

A, adoption; C, continuation.
chance to practice inserting the method on a pelvic model were particularly helpful (Shapiro et al. 2014; Zafar et al. 2019; Das et al. 2015; Schuyler et al. 2016). Effective counseling also includes the opportunity for women to clarify misconceptions and can be supported using educational videos and leaflets (Gottert et al. 2015; Mack, Grey, Amsterdam, Williamson, et al. 2010; Routes2Results et al. 2019a; Ting, Wong, and Tinay 2018; Aung et al. 2019; Karra et al. 2017; Agot et al. 2019; Weinrib et al. 2018).

Alignment between a method's duration of use and women's preferences facilitated the adoption and continued use of all methods except the female condom, which is a single-use, on demand method (Shapiro 2016; Machado et al. 2013; Shapiro et al. 2014; Somesh Kumar et al. 2014; Das et al. 2015; Minnis et al. 2018; Shapley-Quinn et al. 2019; Sheriar et al. 2014; Van Der Straten et al. 2018; Callahan et al. 2019; Van Der Westhuizen and Hanekom 2016; Ndegwa et al. 2014; Jairaj and Dayyala 2016; Eva et al. 2018; Kakaire et al. 2016; FHI360 and Family Health Options Kenya 2016, 360; FHI 360, SFH Nigeria, and PSI 2020b; USAID 2019; PSI et al. 2019; Population Council 2016c; FHI 360 2012; Routes2Results et al. 2019b; Danna et al. 2019; FHI 360 2017; Van Der Straten et al. 2010; Todd et al. 2012; Bryant et al. 2015; Gutin et al. 2011; Ho and Wheeler 2018; Hubacher et al. 2013; Da Costa et al. 2019; Priyanka, Kaushik, and Paras 2015). For example, many studies found that women appreciated the long-acting nature of copper and hormonal IUDs because they saw this duration as convenient and low maintenance (Nanda et al. 2018; Gottert et al. 2015; Huber-Krum et al. 2019; Mukamuyango et al. 2020; Azmat et al. 2012; Boller et al. 2018; Gedeon et al. 2015; Kakaire et al. 2016; FHI 360 2014; Tilahun et al. 2016).

An acceptable side effect profile was influential for the adoption of three methods: the diaphragm and copper and hormonal IUDs (Shapiro 2016; Harris and Angel 2020; Nanda et al. 2018; Shapiro et al. 2014; Huber-Krum et al. 2019; Callahan et al. 2019; Eva et al. 2018; FHI360 and Family Health Options Kenya 2016; FHI 360, SFH Nigeria, and PSI 2020b; USAID 2019; PSI et al. 2019; 2019b; Danna et al. 2019; FHI 360 2017; Bryant et al. 2015; Hubacher et al. 2013; Priyanka, Kaushik, and Paras 2015; Boller et al. 2018; Marston et al. 2016; A. Kumar et al. 2018; Hayes and Kilbourne-Brook 2016b; Kyamwanga et al. 2014; S. Castle et al. 2019; FHI 360, SFH Nigeria, and PSI 2020a). According to the literature reviewed, women perceived the copper IUD (a nonhormonal method) as having fewer side effects than hormonal contraceptive options (Huber-Krum et al. 2019; Bryant et al. 2015; S. Castle et al. 2019; A. Kumar et al. 2018). For hormonal IUDs, the method's treatment of heavy or painful periods and tendency to reduce menstrual bleeding were positive factors for adoption (Nanda et al. 2018; Boller et al. 2018; Callahan et al. 2019; Eva et al. 2018; FHI360 and Family Health Options Kenya 2016; FHI 360, SFH Nigeria, and PSI 2020b; USAID 2019; FHI 360, SFH Nigeria, and PSI 2020a, 2019a, 2019b; Danna et al. 2019; FHI 360 2017; Hubacher et al. 2013). In addition, women often adopted the diaphragm, female condom, and copper IUD due to a preference for nonhormonal methods (Harris and Angel 2020; Miller et al. 2018; Somesh Kumar et al. 2014; Huber-Krum et al. 2019; Boller et al. 2018; Tilahun et al. 2016; Bryant et al. 2015; Callahan et al. 2019; Da Costa et al. 2019; Blumenthal et al. 2016; Marston et al. 2016; Scavuzzi, Souza, and Amorim 2016; Mahlalela and Maharaj 2015; Jairaj and Dayyala 2016; Hayes and Kilbourne-Brook 2016b; Kyamwanga et al. 2014; Mathenjwa and Maharaj 2012; Van Der Westhuizen and Hanekom 2016). Many women saw the ability to use a method while breastfeeding as a positive factor (Huber-Krum et al. 2019; Eva et al. 2018; Routes2Results et al. 2019b; Danna et al. 2019).

September 2022  Studies in Family Planning 53(3)
Dual protection and advances in product design were also associated with method adoption. Women liked that the female condom provided dual protection from pregnancy and HIV (as well as some sexually transmitted infections [STIs]; Miller et al. 2018; Schuyler et al. 2016; Mahlalela and Maharaj 2015; Protection Options for Women Product Development Partnership (POW PDP) 2015; Wang et al. 2015; Mathenjwa and Maharaj 2012; Van Dijk et al. 2013; Naidu 2013; Coffey et al. 2013; Mokgetse and Ramukumba 2018) and that the diaphragm and vaginal ring had the potential to offer dual protection in the future (e.g., in combination with a microbicide for the diaphragm, co-formulated vaginal rings; Shapiro 2016; Hayes and Kilbourne-Brook 2016a; Das et al. 2015). Additionally, the literature showed that women considered the reversibility of the vaginally inserted products as a positive attribute (Gottert et al. 2015; Huber-Krum et al. 2019; Van Der Westhuizen and Hanekom 2016; Jairaj and Dayyala 2016; Danna et al. 2019; Todd et al. 2012; Tilahun et al. 2016) and valued methods that offered an immediate return to fertility after discontinuation (Huber-Krum et al. 2019; Eva et al. 2018; Routes2Results et al. 2019b; Todd et al. 2012; USAID 2019; Gutin et al. 2011). Women also noted improved product designs (e.g., material) and their own interest in trying a new product as enablers to adoption (Miller et al. 2018; FHI 360 2017; POW PDP 2015; Bekinska et al. 2019; Bowling et al. 2018; Mokgetse and Ramukumba 2018; Van Dijk et al. 2013).

Receiving a recommendation from a provider, friend, or family member was an important enabler for method adoption, particularly for the female condom, copper IUD, and hormonlal IUD (Harris and Angel 2020; Nanda et al. 2018; Gottert et al. 2015; Azmat et al. 2012; Boller et al. 2018; Gedeon et al. 2015; Eva et al. 2018; FHI360 and Family Health Options Kenya 2016, 360; Danna et al. 2019; POW PDP 2015). As expected, user satisfaction with a chosen method was linked to the continuation of most methods (RamaRao et al. 2018; Miller et al. 2018; Nanda et al. 2018; Somesh Kumar et al. 2014; Ting, Wong, and Tnay 2018; Agot et al. 2019; Minnis et al. 2018; Ndegwa et al. 2014; Eva et al. 2018; Kakaire et al. 2016; Azmat et al. 2012; FHI 360, SFHI Nigeria, and PSI 2020a; Blumenthal et al. 2016; Scavuzzi, Souza, and Amorim 2016; Van Dijk et al. 2013; Santibenchakul and Jaisamrarn 2016; Sodje et al. 2016; Wanyenze et al. 2011; Bharadwaj 2015; Pandit et al. 2014; Joanis et al. 2011; Kestelyn et al. 2018; Dam et al. 2015; Radwan et al. 2019; Park, Nguyen, and Ngo 2011; Ezegwui et al. 2013; Wu et al. 2019; Moagi, Snyman, and Makin 2019; Das et al. 2016).

Partner sexual satisfaction and support were also commonly cited as enablers for method continuation. Findings about sexual satisfaction ranged from not detecting the method during sex (e.g., the diaphragm, vaginal ring) to feeling like the method enhanced the sexual experience (e.g., using a female instead of a male condom) (POW PDP 2015; Mathenjwa and Maharaj 2012; Van Dijk et al. 2013; Bekinska et al. 2019; Bowling et al. 2018; Minnis et al. 2018; Bharadwaj 2015; Pandit et al. 2014; Sahin-Hodoglugil et al. 2011; Kestelyn et al. 2018). According to the literature, partners’ supportive attitudes toward a method also contributed to women’s method continuation (Somesh Kumar et al. 2014; Bryant et al. 2015; Pandit et al. 2014; Wanyenze et al. 2011; Soni, Garg, and Bangar 2013; Malik et al. 2014; Mantell et al. 2020).

**Barriers**

A lack of awareness about all of the vaginally inserted methods was widespread and posed a barrier to adoption (McDonald-Mosley et al. 2010; Miller et al. 2018; K. Thapa et al. 2019;
Huber-Krum et al. 2019; Das et al. 2015; Mack, Grey, Amsterdam, Williamson, et al. 2010; Agot et al. 2019; Ndegwa et al. 2014; FHI360 and Family Health Options Kenya 2016, 360; FHI 360 2012; Van Der Straten et al. 2010; Gutin et al. 2011; Ho and Wheeler 2018; Gedeon et al. 2015; Marston et al. 2016; Kyamwanga et al. 2014; Scavuzzi, Souza, and Amorim 2016; Mahlalela and Maharaj 2015; POW PDP 2015; Bowling et al. 2018; Mack, Grey, Amsterdam, Matta, et al. 2010; Van Zijl, Morroni, and Van Der Spuy 2010; Nigam et al. 2018; Taapopi and Van Der Westhuizen 2019; Davidson et al. 2017; Eliason et al. 2013; Ezugwu et al. 2020; Beksinska et al. 2020; Robinson et al. 2016; Gambir et al. 2019; Chipfuwa et al. 2014). The literature revealed that few women had heard of the methods included in this review from their providers, friends and relatives, or more mainstream sources, such as the media.

According to the literature, product cost was also a major barrier to adoption across all methods (Das et al. 2015; Mack, Grey, Amsterdam, Williamson, et al. 2010; Routes2Results et al. 2019a; Callahan et al. 2019; FHI360 and Family Health Options Kenya 2016, 360; Population Council 2016c; Routes2Results et al. 2019b; Danna et al. 2019; FHI 360 2017; Gedeon et al. 2015; Kyamwanga et al. 2014; FHI 360, SFH Nigeria, and PSI 2020a; Coffey et al. 2013; Wanyenze et al. 2011; Gambir et al. 2019; Population Council 2016d; 2016e; 2016f; 2016g; Liambila et al. 2015; Rashida et al. 2017; Population Council 2016a; Tibaijuka et al. 2017; Silva-Filho et al. 2016). Costs included upfront and recurring costs (e.g., resupplying gel for diaphragm use, single-use female condoms), those related to removal services for IUDs, and any other incidentals, such as the cost of managing side effects (Population Council 2016c). Cost barriers arose not only in the private sector but also in the public sector in cases where additional fees were charged (Callahan et al. 2019; Population Council 2016d).

Unsupportive partner attitudes or outright disapproval were barriers to adoption and continuation for all methods except the hormonal IUD (for which it was not a prominent barrier) (RamaRao et al. 2018; McDonald-Mosley et al. 2010; K. Thapa et al. 2019; Somekumar et al. 2014; Das et al. 2015; Schuyler et al. 2016; Agot et al. 2019; Shapley-Quinn et al. 2019; Sheriar et al. 2014; Van Der Straten et al. 2018; Ndegwa et al. 2014; Jairaj and Dayyala 2016; Azmat et al. 2012; Gedeon et al. 2015; Tilahun et al. 2016; A. Kumar et al. 2018; S. Castle et al. 2019; Blumenthal et al. 2016; Mahlalela and Maharaj 2015; POW PDP 2015; Coffey et al. 2013; Kestelyn et al. 2018; Ezegwui et al. 2013; Moagi, Snyman, and Makin 2019; Sahin-Hodoglugil et al. 2011; Kestelyn et al. 2018; Malik et al. 2014; Mack, Grey, Amsterdam, Matta, et al. 2010; Nigam et al. 2018; Robinson et al. 2016; Gambir et al. 2019; Chipfuwa et al. 2014; Animen, Lake, and Mekuriaw 2018; Agha 2010; Wang, Liu, and Cheng 2016; Martin et al. 2016; Husain, Husain, and Izhar 2019; Enyindah, Ojule, and Bassey 2012; Kathpalia and Mustafá 2015; Huda et al. 2014; Khatri et al. 2019; Teshome et al. 2020; Morineau 2011; Robabi et al. 2016; Divakar et al. 2019; Goswami, Yadav, and Patel 2015; Takele, Dega, and Yitayal 2012; Masvawure et al. 2014; Puri et al. 2020). For some women, this was tied to the covert use of certain methods; of the five methods included in this review, only female condoms are visible to male partners (PSI et al. 2019; Sahin-Hodoglugil et al. 2011).

Another barrier to adoption was women’s concerns about insertion. This was true for all methods except the copper IUD, for which insertion fears were not named in the literature as a major barrier (RamaRao et al. 2018; Shapiro 2016; Harris and Angel 2020; Das et al. 2015; Agot et al. 2019; FHI 360, SFH Nigeria, and PSI 2019b, 2020a, 2020b; Hubacher et al. 2013; Kyamwanga et al. 2014; Coffey et al. 2013; Mokgetse and Ramukumba 2018; Kanda and Mash
2018; Van Der Straten et al. 2010). Some specific concerns cited in the literature were the size of the method (e.g., vaginal ring, female condom), whether the method would remain in place or become dislodged during sex or other activities, and whether insertion would be painful. Of the 182 studies included in the analysis, only six found that women explicitly stated their discomfort touching their vaginas to insert the method or that they felt embarrassed about the insertion process, especially if the provider was male (Agot et al. 2019; FHI 360, SFH Nigeria, and PSI 2020b; Van Der Straten et al. 2010; Hubacher et al. 2013; S. Castle et al. 2019; Robinson et al. 2016).

Anticipated (RamaRao et al. 2018; Nanda et al. 2018; K. Thapa et al. 2019; Gottert et al. 2015; Huber-Krum et al. 2019; Das et al. 2015; Agot et al. 2019; Callahan et al. 2019; Van Der Westhuizen and Hanekom 2016; Ndegwa et al. 2014; Jairaj and Dayyala 2016; FHI360 and Family Health Options Kenya 2016; FHI 360, SFH Nigeria, and PSI 2019a, 2019b, 2020b; Danna et al. 2019; FHI 360 2017; Gutin et al. 2011; Ho and Wheeler 2018; Hubacher et al. 2013; Da Costa et al. 2019; Mukamuyango et al. 2020; Gedeon et al. 2015; Tilahun et al. 2016; FHI 360, SFH Nigeria, and PSI 2020a; Kestelyn et al. 2018; Radwan et al. 2019; Kestelyn et al. 2018; Van Zijl, Morroni, and Van Der Spuy 2010; Nigam et al. 2018; Ezugwu et al. 2020; Robinson et al. 2016; Rashida et al. 2017; Animen, Lake, and Mekuriai 2018; Kathapalia and Mustafa 2015; Khatri et al. 2019; Teshome et al. 2020; Goswami, Yadav, and Patel 2015; Bulto, Zewdie, and Beyen 2014; Luo et al. 2018; Dereje, Engida, and Holland 2020; Asghar, Homayun, and Awan 2016; Rominski et al. 2017; Abdel-Tawab et al. 2020; Monji Builu and Naidoo 2015; Elkhateeb et al. 2020; Mekonnen et al. 2014) and experienced (RamaRao et al. 2018; Shapiro 2016; Nanda et al. 2018; K. Thapa et al. 2019; Wasim et al. 2018; Somesh Kumar et al. 2014; Huber-Krum et al. 2019; Agot et al. 2019; Jairaj and Dayyala 2016; Eva et al. 2018; Kakaire et al. 2016; FHI360 and Family Health Options Kenya 2016, 360; Population Council 2016c; Bryant et al. 2015; Priyanka, Kaushik, and Paras 2015; Azmat et al. 2012; Gedeon et al. 2015; FHI 360 2014; FHI 360, SFH Nigeria, and PSI 2020a; Blumenthal et al. 2016; Santibenchakul and Jaisamrarn 2016; Kestelyn et al. 2018; Dam et al. 2015; Radwan et al. 2019; Park, Nguyen, and Ngo 2011; Ezugwu et al. 2013; Moagi, Snyman, and Makin 2019; Das et al. 2016; Kestelyn et al. 2018; Malik et al. 2014; Enyindah, Ojule, and Bassey 2012; Huda et al. 2014; Khatri et al. 2019; Robabi et al. 2016; Divakar et al. 2019; Goswami, Yadav, and Patel 2015; Puri et al. 2020; Abdel-Tawab et al. 2020; Hameed et al. 2015; S. Kumar et al. 2019; Maternal and Child Survival Program [MCSP] 2019; Sharma et al. 2014; S. Thapa et al. 2015; Azmat et al. 2013; Landolt et al. 2013) side effects were barriers to the adoption and continuation of the two hormonal methods (the vaginal ring and hormonal IUD) as well as the copper IUD.

Myths and misconceptions about methods were barriers to the adoption of the female condom, copper and hormonal IUDs (Huber-Krum et al. 2019; Van Der Westhuizen and Hanekom 2016; Ndegwa et al. 2014; FHI360 and Family Health Options Kenya 2016, 360; FHI 360, SFH Nigeria, and PSI 2020b; Bryant et al. 2015; Ho and Wheeler 2018; Gedeon et al. 2015; Tilahun et al. 2016; FHI 360, SFH Nigeria, and PSI 2020a; Naidu 2013; Bulto, Zewdie, and Beyen 2014; Agha 2010; Dereje, Engida, and Holland 2020; Nigam et al. 2018; Taapopi and Van Der Westhuizen 2019; Davidson et al. 2017; Robinson et al. 2016; Radwan et al. 2019; Eshak 2020; Abdel-Tawab et al. 2020; Wedderburn et al. 2011; Monji Builu and Naidoo 2015; Gambir et al. 2019; Tibaijuka et al. 2017; Silva-Filho et al. 2016). For both IUDs, women had misconceptions about their eligibility for use due to age, marital status, and/or parity (which...
TABLE 3  Barriers and enablers to adoption and continuation of the diaphragm

| Adoption (n = 10 studies) | Continuation (n = 10 studies) |
|--------------------------|-------------------------------|
| **Enablers**              |                               |
| Acceptable side effect profile | Partner sexual satisfaction |
| Woman-controlled method   | Duration of use               |
| Can be self-inserted and self-removed | Can be used on demand |
| Barriers                  |                               |
| Lack of familiarity with the product | Duration of use |
| Requires lubricant        |                               |

may be due to poor or incomplete contraceptive counseling by providers) (Huber-Krum et al. 2019; Van Der Westhuizen and Hanekom 2016; Robinson et al. 2016; Taapopi and Van Der Westhuizen 2019). Fear that the method would move around the body was a particularly common myth cited in the literature (Das et al. 2015; Agot et al. 2019; Van Der Westhuizen and Hanekom 2016; Ndegwa et al. 2014; FHI 360, SFH Nigeria, and PSI 2020b; Bryant et al. 2015; Ho and Wheeler 2018; Gedeon et al. 2015; Tilahun et al. 2016; Radwan et al. 2019; Dereje, Engida, and Holland 2020; Eshak 2020). Relatedly, some women worried about the potential for dislodgment or expulsion with the vaginal ring, copper and hormonal IUDs, which does occur although infrequently (Das et al. 2015; Agot et al. 2019; Callahan et al. 2019; Routes2Results et al. 2019b; FHI 360 2017; Kestelyn et al. 2018; Kestelyn et al. 2018; Mekonnen et al. 2014; Ndegwa et al. 2014; Bulto, Zewdie, and Beyen 2014).

Concerns for both women (Rama Rao et al. 2018; Shapiro 2016; Huber-Krum et al. 2019; Callahan et al. 2019; FHI 360 2017; Van Der Straten et al. 2010; FHI 360 2014; Kyamwanga et al. 2014; POW PDP 2015; Coffey et al. 2013; Bharadwaj 2015; Kestelyn et al. 2018; Dam et al. 2015; Park, Nguyen, and Ngo 2011; Das et al. 2016; Kestelyn et al. 2018; Khatri et al. 2019; Bulto, Zewdie, and Beyen 2014; Dereje, Engida, and Holland 2020; Monji Builu and Naidoo 2015; Khan and Shaikh 2013) and their partners (Shapiro 2016; Gottert et al. 2015; Huber-Krum et al. 2019; Agot et al. 2019; Van Der Straten et al. 2010; Kyamwanga et al. 2014; POW PDP 2015; Kestelyn et al. 2018; Dam et al. 2015; Das et al. 2016; X. Wang, Liu, and Cheng 2016; Bulto, Zewdie, and Beyen 2014; Dereje, Engida, and Holland 2020; Khan and Shaikh 2013; Landolt et al. 2013) around sexual satisfaction were mainly focused on methods interfering with sexual activity or pleasure. Some studies noted that women (and their partners) worried that partners would be able to feel the method during sex and may dislike and/or request removal of the method as a result. For the vaginal ring and female condom, physical discomfort with the method—such as feelings of slippage or the sensation of a foreign object inside the vagina—was a barrier to continuation (Bowling et al. 2018; Soni, Garg, and Bangar 2013; Dam et al. 2015; Santibenchakul and Jaisamrarn 2016; Das et al. 2016). Relatedly, some design aspects of the methods, such as the material used for female condoms or copper IUD strings, were barriers to adoption (Schuyler et al. 2016; Naidu 2013; Huda et al. 2014; Zhou et al. 2019).

In the following sections, we identify enablers and barriers to adoption and continuation unique to each of the vaginally inserted methods of contraception reviewed.

Diaphragm

Diaphragm-specific enablers and barriers to adoption and continuation are listed in Table 3.
Enablers

Similar to the findings for other vaginally inserted methods (Table 2), a lack of side effects due to the absence of hormones was an important enabler for adoption of the diaphragm (Shapiro 2016; Harris and Angel 2020; Shapiro et al. 2014; Kyamwanga et al. 2014; Hayes and Kilbourne-Brook 2016b). Other enabling factors for adoption were that the diaphragm is a woman-controlled method (Shapiro 2016; Shapiro et al. 2014; Hayes and Kilbourne-Brook 2016b; Van Der Straten et al. 2010; Sahin-Hodoglugil et al. 2011) and can be inserted and removed by the woman herself (Van Der Straten et al. 2010; Beksinska et al. 2018). Users liked the diaphragm’s duration of use (Van Der Straten et al. 2010; Coffey and Kilbourne-Brook 2010) and that it can be used on demand as needed (Harris and Angel 2020), both of which were linked with method continuation. An important factor that was unique to the diaphragm was the ability to wash and reuse the method for up to two years (Shapiro 2016; Shapiro et al. 2014; Sahin-Hodoglugil et al. 2011). Women’s sexual partners appreciated that the diaphragm preserved skin-to-skin contact during sex, and some welcomed the use of a gel (Sahin-Hodoglugil et al. 2011).

Barriers

The most common barrier cited in the literature for adoption of the diaphragm was a lack of familiarity with the product (Kyamwanga et al. 2014; Van Der Straten et al. 2010; Eliason et al. 2013), which is similar to other methods listed in Table 2. The diaphragm is a relatively unfamiliar product category in many LMIC markets. The requirement to use a gel with the diaphragm to facilitate insertion and create a seal between the diaphragm and the vaginal walls is a unique barrier for adoption of this method (Kyamwanga et al. 2014; Van Der Straten et al. 2010; Beksinska et al. 2018). According to the literature, for some women, using gel during sex is not acceptable or desirable (Kyamwanga et al. 2014; Van Der Straten et al. 2010). It also presents a recurring cost (Kyamwanga et al. 2014). Other barriers to adoption were women’s concerns about their ability to correctly insert the diaphragm (Shapiro 2016; Harris and Angel 2020; Kyamwanga et al. 2014), the need to touch their vagina to insert it (Van Der Straten et al. 2010), and whether the diaphragm would be comfortable and remain in place (Shapiro 2016; Shapiro et al. 2014; Kyamwanga et al. 2014). Women also had differing opinions about the appeal of wearing the diaphragm continuously versus episodically (Van Straten et al. 2010). Currently, the diaphragm is indicated for episodic use, which means that it must be inserted before sex and removed no sooner than 6 hours after sex (at which point most sperm cells are no longer active).

Vaginal Ring

Vaginal ring-specific enablers and barriers to adoption and continuation are listed in Table 4.

Enablers

In line with the findings for other vaginally inserted methods (Table 2), the availability and quality of in-person counseling on how to use the method (Machado et al. 2013; Das et al. 2015; Das et al. 2016), including educational videos and demonstrations (Das et al. 2015; Agot et al. 2019; Weinrib et al. 2018; Dam et al. 2015), were enablers to adoption of the vaginal ring.
TABLE 4  Barriers and enablers to adoption and continuation of the vaginal ring

| Adoption (n = 13 studies) | Continuation (n = 13 studies) |
|---------------------------|--------------------------------|
| **Enablers**              | **Continuation (n = 13 studies)** |
| Use of counseling tools   | Satisfaction with use           |
| Counseling by a trained provider or community health worker | Comfort with self-insertion |
| Duration of use           | User sexual satisfaction        |
| **Barriers**              |                                |
| Concerns about product performance | Concerns about product performance |
| Partner attitudes         | Comfort and fit                 |
| Anticipated side effects  | Experienced side effects        |

The literature revealed that women also appreciate the vaginal ring’s one-month duration of use, which alleviates concerns about forgetting to use contraception (Machado et al. 2013; Das et al. 2015; Sheriar et al. 2014). Overall satisfaction with the vaginal ring increased over time and was an enabling factor for continuation of the method (Agot et al. 2019; Das et al. 2016; Dam et al. 2015; Santibenchakul and Jaisamrarn 2016; Minnis et al. 2018; Pandit et al. 2014; Kestelyn et al. 2018; RamaRao et al. 2018). Similarly, users’ comfort with self-insertion of the vaginal ring increased over time, with many reporting during endline assessments that insertion was “easy” (Das et al. 2016; Dam et al. 2015; Minnis et al. 2018; Pandit et al. 2014; Kestelyn et al. 2018; RamaRao et al. 2018; Shapley-Quinn et al. 2019; Van Der Straten et al. 2018; Kestelyn et al. 2018; Soni, Garg, and Bangar 2013). According to the literature, most users did not report feeling the vaginal ring during sex (Pandit et al. 2014; Kestelyn et al. 2018; Kestelyn et al. 2018), but some women thought that the ring increased their sexual pleasure (Kestelyn et al. 2018; Kestelyn et al. 2018). Relatedly, some women reported that the ring increased vaginal lubrication (Kestelyn et al. 2018) and viewed this change positively in terms of sexual satisfaction.

**Barriers**

Concerns about product performance, such as effectiveness and spontaneous expulsion, were the most cited barriers to adoption of the vaginal ring (Das et al. 2015; Agot et al. 2019; Kestelyn et al. 2018; Kestelyn et al. 2018). Women also worried about convincing their partners to try the relatively new method, especially if there was shared decision-making around contraceptive use and the associated costs (Das et al. 2015; Agot et al. 2019; Sheriar et al. 2014; Kestelyn et al. 2018). Since the vaginal ring is a hormonal method, anticipated side effects were also a commonly cited barrier to adoption of the method (Das et al. 2015; Kestelyn et al. 2018; RamaRao et al. 2018; Kestelyn et al. 2018). Ongoing concerns about comfort and fit, such as slippage, expulsion and the sensation of a foreign object in the vagina, were barriers to continuation of the vaginal ring (Agot et al. 2019; Das et al. 2016; Dam et al. 2015; Santibenchakul and Jaisamrarn 2016; Kestelyn et al. 2018; RamaRao et al. 2018; Kestelyn et al. 2018; Soni, Garg, and Bangar 2013), although there were only a few studies documenting women experiencing such events (Roy et al. 2020; Das et al. 2016; Dam et al. 2015; RamaRao et al. 2018; Kestelyn et al. 2018). For women who experienced side effects, such as changes in menstrual bleeding, these effects were a barrier to continuation (Agot et al. 2019; Das et al. 2016; Dam et al. 2015; Santibenchakul and Jaisamrarn 2016; Kestelyn et al. 2018; RamaRao et al. 2018; Kestelyn et al. 2018).
### Table 5: Barriers and enablers to adoption and continuation of the female condom

| Adoption (n = 36 studies) | Continuation (n = 21 studies) |
|---------------------------|-------------------------------|
| **Enablers**              |                               |
| Provides dual protection  | Partner sexual satisfaction   |
| Woman-controlled method   | User sexual satisfaction      |
| Ability to negotiate use with partner | Woman-controlled method |
| **Barriers**              |                               |
| Lack of familiarity with the product | Comfort and fit |
| Partner attitudes         | Partner attitudes             |
| Size of the product       | Partner sexual satisfaction   |

**Female Condom**

Female condom-specific enablers and barriers to adoption and continuation are listed in Table 5.

**Enablers**

User control over the method was a commonly cited enabler for both the adoption and continuation of the female condom (Schuyler et al. 2016; POW PDP 2015; Bowling et al. 2018; Van Dijk et al. 2013; Martin et al. 2016; Kanda and Mash 2018; Wanyenze et al. 2011; Mahlalela and Maharaj 2015; Gambir et al. 2019; Mathenjwa and Maharaj 2012; Masvawure et al. 2014). Other enablers for adoption were the dual protection female condoms provide against both pregnancy and STIs/HIV (Miller et al. 2018; Schuyler et al. 2016; POW PDP 2015; Mokgetse and Ramukumba 2018; Van Dijk et al. 2013; Mahlalela and Maharaj 2015; Mathenjwa and Maharaj 2012; Wang et al. 2015; Naidu 2013; Coffey et al. 2013) and an increased ability to negotiate use with partners due to the woman-controlled nature of the method (Miller et al. 2018; Schuyler et al. 2016; Van Dijk et al. 2013; Martin et al. 2016; Mathenjwa and Maharaj 2012; Mack, Grey, Amsterdam, Matta, et al. 2010; Gomez et al. 2018). Sexual satisfaction during use by both the user (POW PDP 2015; Bowling et al. 2018; Mathenjwa and Maharaj 2012) and the partner (POW PDP 2015; Beksinska et al. 2019; Bowling et al. 2018; Van Dijk et al. 2013; Mathenjwa and Maharaj 2012; Bharadwaj 2015) were benefits that supported continuation. Unlike the findings for other vaginally inserted methods, a lack of side effects was not a theme that appeared frequently in the literature for this method.

**Barriers**

The most cited barriers to the use of the female condom—lack of familiarity with the product (Miller et al. 2018; Mack, Grey, Amsterdam, Williamson, et al. 2010; POW PDP 2015; Bowling et al. 2018; Mahlalela and Maharaj 2015; Gambir et al. 2019; Mack, Grey, Amsterdam, Matta, et al. 2010; Beksinska et al. 2020; Chipfuwa et al. 2014), partner attitudes (Schuyler et al. 2016; POW PDP 2015; Martin et al. 2016; 2016; Mahlalela and Maharaj 2015; Gambir et al. 2019; Masvawure et al. 2014; Coffey et al. 2013; Mack, Grey, Amsterdam, Matta, et al. 2010; Chipfuwa et al. 2014; Wang, Liu, and Cheng 2016; Morineau 2011), comfort and fit (Schuyler et al. 2016; Naidu 2013; Zhou et al. 2019), and partner’s sexual satisfaction (POW PDP 2015; Wang, Liu, and Cheng 2016)—were similar to the other methods listed in Table 2. The size of the product was a barrier for some female condoms, with a common complaint being that the condom and its inner ring (e.g., with FC2) were too large (Schuyler et al. 2016; Mack,
Grey, Amsterdam, Williamson, et al. 2010; Mokgetse and Ramukumba 2018; Kanda and Mash 2018; Naidu 2013; Wedderburn et al. 2011). Interestingly, partner sexual satisfaction was cited as both an enabler and barrier to continuation. Issues around the product’s size, comfort, and fit may be associated with this finding.

### Copper IUD

Copper IUD-specific enablers and barriers to adoption and continuation are listed in Table 6.

#### Enablers

Effective in-person contraceptive counseling was an important factor for adoption and a unique enabler for continuation of the copper IUD (McDonald-Mosley et al. 2010; Vakilian et al. 2018; K. Thapa et al. 2019; Makins et al. 2018; Gottert et al. 2015; Wasim et al. 2018; Zafar et al. 2019; Eluwa et al. 2016; Karra et al. 2019; Somesh Kumar et al. 2014; Huber-Krum et al. 2019; Karra et al. 2017; Gedeon et al. 2015; A. Kumar et al. 2018; Malik et al. 2014; Animen, Lake, and Mekuriaw 2018; Blumenthal et al. 2016; Santhya et al. 2014; Azmat et al. 2013; Radwan et al. 2019; Ambadekar, Rathod, and Zodpey 2010; Elkateeb et al. 2020; Mazzei et al. 2019; Puri et al. 2020). According to the literature, copper IUD users benefited from postadoption touch points with health care workers, who supported continued use through management of side effects, notably heavy bleeding (Huber-Krum et al. 2019). The duration of the product was also important to users for both adopting and continuing the method (Gottert et al. 2015; Somesh Kumar et al. 2014; Huber-Krum et al. 2019; Mukamuyango et al. 2020; Azmat et al. 2012; Gedeon et al. 2015; Kakaire et al. 2016; FHI 360 2014; Tilahun et al. 2016; Bryant et al. 2015; Callahan et al. 2019; FHI 360 2017; Van Der Westhuizen and Hanekom 2016; Jairaj and Dayyala 2016; Gutin et al. 2011; Blumenthal et al. 2016; Ndegwa et al. 2014; Da Costa et al. 2019; Population Council 2016c; Priyanka, Kaushik, and Paras 2015; Ho and Wheeler 2018; FHI 360 2012; Population Council 2016b). For the copper IUD, the 10 years of protection provided many women with “freedom from worry” since they did not have to remember to use contraception more frequently (Gottert et al. 2015). Compared to hormonal methods, the nonhormonal nature of the copper IUD was a benefit to many women (Somesh Kumar et al. 2014; Huber-Krum et al. 2019; Boller et al. 2018; Tilahun et al. 2016; Bryant et al. 2015; Callahan et al. 2019; Van Der Westhuizen and Hanekom 2016; Jairaj and Dayyala 2016; Blumenthal et al. 2016; Da Costa et al. 2019; Marston et al. 2016; Scavuzzi, Souza, and Amorim 2016), who perceive nonhormonal methods to have fewer side effects (Huber-Krum et al. 2019; Boller et al. 2018; Bryant et al. 2015; S. Castle et al. 2019; A. Kumar et al. 2018; FHI 360

| Adoption (n = 90 studies) | Continuation (n = 43 studies) |
|--------------------------|-------------------------------|
| **Enablers**             | **Satisfaction with use**     |
| Counseling by a trained provider or community health worker | Counseling by a trained provider or community health worker |
| Duration of use           | Duration of use               |
| Acceptable side effect profile |                           |
| Anticipated side effects  | Experienced side effects      |
| Myths and misconceptions about product | Concerns about product performance |
| Partner attitudes         | Partner attitudes             |

*Source: Studies in Family Planning 53(3)*
2017; Marston et al. 2016; Priyanka, Kaushik, and Paras 2015) (copper IUD side effects differ from hormonal contraceptive side effects). Women also adopted the method to maintain monthly menstruation (Huber-Krum et al. 2019; Boller et al. 2018; Bryant et al. 2015; S. Castle et al. 2019; FHI 360 2017). Satisfaction with the product after adoption was associated with continued use (Somesh Kumar et al. 2014; Azmat et al. 2012; Kakraire et al. 2016; FHI 360, SFH Nigeria, and PSI 2020a; Blumenthal et al. 2016; Radwan et al. 2019; Ndegwa et al. 2014; Sodje et al. 2016; Scavuzzi, Souza, and Amorim 2016; Park, Nguyen, and Ngo 2011; Ezugwu et al. 2013; Moagi, Snyman, and Makin 2019), and women often expressed their satisfaction in their willingness to recommend the copper IUD to others (Azmat et al. 2012; Gedeon et al. 2015; FHI 360, SFH Nigeria, and PSI 2020a; Blumenthal et al. 2016; Sodje et al. 2016; Park, Nguyen, and Ngo 2011; Scavuzzi, Souza, and Amorim 2016).

**Barriers**

Myths and misconceptions surrounding the copper IUD were significant barriers to adoption (Huber-Krum et al. 2019; Gedeon et al. 2015; Tilahun et al. 2016; Bryant et al. 2015; Van Der Westhuizen and Hanekom 2016; Radwan et al. 2019; Ndegwa et al. 2014; Ho and Wheeler 2018; Bulto, Zewdie, and Beyen 2014; Agha 2010; Dereje, Engida, and Holland 2020; Nigam et al. 2018; Taappoi and Van Der Westhuizen 2019; Davidson et al. 2017; Eshak 2020; Abdel-Tawab et al. 2020; Robinson et al. 2016; Tibaijuka et al. 2017; Monji Builu and Naidoo 2015; Silva-Filho et al. 2016). Common misunderstandings cited in the literature include that the IUD may get lost in the body (Gedeon et al. 2015; Tilahun et al. 2016; Bryant et al. 2015; Van Der Westhuizen and Hanekom 2016; Radwan et al. 2019; Ndegwa et al. 2014; Dereje, Engida, and Holland 2020; Eshak 2020; Ho and Wheeler 2018); it causes cancer (Huber-Krum et al. 2019; Gedeon et al. 2015; Tilahun et al. 2016; Van Der Westhuizen and Hanekom 2016; Ndegwa et al. 2014; Taappoi and Van Der Westhuizen 2019; Dereje, Engida, and Holland 2020; Ho and Wheeler 2018; Davidson et al. 2017); and it is inappropriate for nonparous women (Taappoi and Van Der Westhuizen 2019; Robinson et al. 2016). Side effects, both anticipated (K. Thapa et al. 2019; Gottert et al. 2015; Huber-Krum et al. 2019; Mukamuyango et al. 2020; Gedeon et al. 2015; Tilahun et al. 2016; Callahan et al. 2019; FHI 360 2017; Van Der Westhuizen and Hanekom 2016; Jairaj and Dayyala 2016; Gutin et al. 2011; Animen, Lake, and Mekuriaw 2018; Radwan et al. 2019; Elkhateeb et al. 2020; Ndegwa et al. 2014; Da Costa et al. 2019; Ho and Wheeler 2018; Bulto, Zewdie, and Beyen 2014; Dereje, Engida, and Holland 2020; Nigam et al. 2018; Abdel-Tawab et al. 2020; Robinson et al. 2016; Monji Builu and Naidoo 2015; Van Zijl, Morroni, and Van Der Spuy 2010; Luo et al. 2018; Kathpalia and Mustafa 2015; Khatri et al. 2019; Teshome et al. 2020; Ezugwu et al. 2020; Asghar, Homayun, and Awan 2016; Rominiski et al. 2017; Rashida et al. 2017; Goswami, Yadav, and Patel 2015; Mekonnen et al. 2014) and experienced (Shapiro 2016; K. Thapa et al. 2019; Wasim et al. 2018; Somesh Kumar et al. 2014; Huber-Krum et al. 2019; Jairaj and Dayyala 2016; Kakraire et al. 2016; Population Council 2016c; Bryant et al. 2015; Priyanka, Kaushik, and Paras 2015; Gedeon et al. 2015; FHI 360 2014; FHI 360, SFH Nigeria, and PSI 2020a; Blumenthal et al. 2016; Malik et al. 2014; Radwan et al. 2019; Abdel-Tawab et al. 2020; Huda et al. 2014; Azmat et al. 2013; Puri et al. 2020; Population Council 2016b; Park, Nguyen, and Ngo 2011; Ezugwu et al. 2013; Moagi, Snyman, and Makin 2019; Khatri et al. 2019; Goswami, Yadav, and Patel 2015; Hameed et al. 2015; S. Kumar et al. 2015; FHI 360 2017; SFH Nigeria, and PSI 2020a; Blumenthal et al. 2016; Malik et al. 2014; Radwan et al. 2019; Abdel-Tawab et al. 2020; Huda et al. 2014; Azmat et al. 2013; Puri et al. 2020; Population Council 2016b; Park, Nguyen, and Ngo 2011; Ezugwu et al. 2013; Moagi, Snyman, and Makin 2019; Khatri et al. 2019; Goswami, Yadav, and Patel 2015; Hameed et al. 2015; S. Kumar et al.
Barriers and Enablers to Use of Vaginally Inserted Contraceptive Methods

TABLE 7 Barriers and enablers to adoption and continuation of the hormonal IUD

| Adoption (n = 18 studies) | Continuation (n = 9 studies) |
|--------------------------|------------------------------|
| **Enablers**             |                              |
| Acceptable side effect profile | Experienced side effects |
| Duration of use           | Sense of empowerment          |
| Effectiveness             | Satisfaction with the method |
| Barriers                  |                              |
| Anticipated side effects  | Experienced side effects     |
| Cost                      |                              |
| Concerns about insertion  |                              |

2019; Enyindah, Ojule, and Bassey 2012; Sharma et al. 2014; Landolt et al. 2013; Robabi et al. 2016; Divakar et al. 2019), were the most common barriers to the adoption and continuation of the copper IUD. The copper IUD was the only nonhormonal method where side effects played a key role in women’s decision not to adopt or continue to use it. Prior to use, women feared pain, bleeding, infertility, increased risk of cancer or other health effects, and the device causing internal damage. Menstrual bleeding changes were the most significant side effects hindering product continuation (Shapiro 2016; K. Thapa et al. 2019; Wasim et al. 2018; Somesh Kumar et al. 2014; Huber-Krum et al. 2019; Jairaj and Dayyala 2016; Population Council 2016c; Priyanka, Kaushik, and Paras 2015; Azmat et al. 2012; FHI 360 2014; FHI 360, SFH Nigeria, and PSI 2020a; Blumenthal et al. 2016; Malik et al. 2014; Radwan et al. 2019; Abdel-Tawab et al. 2020; Huda et al. 2014; Azmat et al. 2013; Puri et al. 2020; Park, Nguyen, and Ngo 2011; Ezegwui et al. 2013; Moagi, Snyman, and Makin 2019; Enyindah, Ojule, and Bassey 2012; Landolt et al. 2013; Robabi et al. 2016). A lack of partner support was a key barrier for both the adoption and continuation of the copper IUD (McDonald-Mosley et al. 2010; K. Thapa et al. 2019; Somesh Kumar et al. 2014; Azmat et al. 2012; Gedeon et al. 2015; Tilahun et al. 2016; S. Castle et al. 2019; A. Kumar et al. 2018; Jairaj and Dayyala 2016; Malik et al. 2014; Animen, Lake, and Mekuriaw 2018; Blumenthal et al. 2016; Puri et al. 2020; Ndegwa et al. 2014; Ezegwui et al. 2013; Moagi, Snyman, and Makin 2019; Agha 2010; Nigam et al. 2018; Robinson et al. 2016; Husain, Husain, and Izhar 2019; Enyindah, Ojule, and Bassey 2012; Kathpalia and Mustafa 2015; Khatri et al. 2019; Teshome et al. 2020; Huda et al. 2014; Robabi et al. 2016; Divakar et al. 2019; Goswami, Yadav, and Patel 2015; Takele, Degu, and Yitayal 2012); however, most studies did not cite specific reasons for partner disapproval. Poor product performance during use (expulsion or migration of the copper IUD) was a barrier unique to the continuation of the copper IUD (K. Thapa et al. 2019; Huber-Krum et al. 2019; Azmat et al. 2012; Gedeon et al. 2015; Jairaj and Dayyala 2016; Radwan et al. 2019; Scavuzzi, Souza, and Amorim 2016; Sodje et al. 2016; Park, Nguyen, and Ngo 2011; Ezegwui et al. 2013; S. Kumar et al. 2019; Enyindah, Ojule, and Bassey 2012; Robabi et al. 2016; Goswami, Yadav, and Patel 2015).

**Hormonal IUD**

Hormonal IUD-specific enablers and barriers to adoption and continuation are listed in Table 7.
**Enablers**

One of the enabling factors for the adoption and continuation of the hormonal IUD was its acceptable side effect profile (Nanda et al. 2018; Boller et al. 2018; Eva et al. 2018; Routes2Results et al. 2019b; Danna et al. 2019; USAID 2019; FHI 360 2017; Hubacher et al. 2013; PSI et al. 2019; Callahan et al. 2019; FHI 360, SFH Nigeria, and PSI 2020b; FHI360 and Family Health Options Kenya 2016; FHI 360, SFH Nigeria, and PSI 2020a). Despite being a hormonal method, many women chose the hormonal IUD because they anticipated fewer side effects than other hormonal methods, such as the implant (Nanda et al. 2018; Hubacher et al. 2013). Reduced menstrual bleeding was considered a benefit to many women (Nanda et al. 2018; Boller et al. 2018; Eva et al. 2018; Routes2Results et al. 2019b; Danna et al. 2019; USAID 2019; FHI 360 2017; Hubacher et al. 2013; PSI et al. 2019; Callahan et al. 2019; FHI 360, SFH Nigeria, and PSI 2020b; FHI360 and Family Health Options Kenya 2016; FHI 360, SFH Nigeria, and PSI 2020a), and some adopted the hormonal IUD as a treatment for heavy or painful periods (Eva et al. 2018; FHI 360 2017; PSI et al. 2019; Callahan et al. 2019; FHI 360, SFH Nigeria, and PSI 2020a). As with other methods, alignment between the method’s duration of use and user preferences was an important enabling factor for adoption (Nanda et al. 2018; Eva et al. 2018; Routes2Results et al. 2019b; Danna et al. 2019; USAID 2019; FHI 360 2017; Hubacher et al. 2013; PSI et al. 2019; Callahan et al. 2019; FHI 360, SFH Nigeria, and PSI 2020b; FHI360 and Family Health Options Kenya 2016; Maternal and Child Survival Program [MCSP] 2019). According to the literature, women often chose the hormonal IUD for its long-acting duration, and some preferred the three-to-five-year duration, depending on the specific product, over the 10 years of protection that the copper IUD offers (Nanda et al. 2018; Danna et al. 2019; FHI 360 2017; Hubacher et al. 2013; Callahan et al. 2019). A unique enabling factor for the adoption of the hormonal IUD was its anticipated performance, notably its high efficacy (Nanda et al. 2018; Routes2Results et al. 2019a; Eva et al. 2018; Routes2Results et al. 2019b; Danna et al. 2019; USAID 2019; PSI et al. 2019; Zhao et al. 2014). It is noteworthy that the literature highlighted how women ascribed a higher efficacy to the hormonal IUD over the similarly efficacious copper IUD. The hormonal IUD had two enabling factors that were unique to its continued use. One was an acceptable side effect profile; women frequently cited reduced menses as a benefit of continued use (Nanda et al. 2018; Eva et al. 2018; FHI 360, SFH Nigeria, and PSI 2020a). The other was a feeling of empowerment that women experienced while using the method (Nanda et al. 2018), possibly due to reduced menses.

**Barriers**

Similar to the copper IUD, both anticipated (Nanda et al. 2018; Routes2Results et al. 2019b; Danna et al. 2019; FHI 360 2017; Hubacher et al. 2013; PSI et al. 2019; Callahan et al. 2019; FHI 360, SFH Nigeria, and PSI 2020b; FHI360 and Family Health Options Kenya 2016; FHI 360, SFH Nigeria, and PSI 2020a) and experienced (Nanda et al. 2018; Eva et al. 2018; FHI360 and Family Health Options Kenya 2016, FHI 360, SFH Nigeria, and PSI 2020a; Maternal and Child Survival Program [MCSP] 2019) side effects were the most common barriers to adoption and continuation of the hormonal IUD. While some women benefited from reduced menses and/or amenorrhea, others viewed this side effect negatively and consequently discontinued the method (Eva et al. 2018; Danna et al. 2019; FHI 360 2017; PSI et al. 2019; 2020b; FHI360
and Family Health Options Kenya 2016, 360; FHI 360, SFH Nigeria, and PSI 2020a). Similar to the findings for other vaginally inserted methods in Table 2, cost was a significant barrier to the adoption of the hormonal IUD (Routes2Results et al. 2019a; Routes2Results et al. 2019b; Danna et al. 2019; FHI360 and Family Health Options Kenya 2016, 360; FHI 360, SFH Nigeria, and PSI 2020a; Silva-Filho et al. 2016). Concerns about vaginal insertion were also a barrier to adoption (Routes2Results et al. 2019b; Hubacher et al. 2013; FHI 360, SFH Nigeria, and PSI 2020b; 2020a), primarily due to fears about pain and, to a lesser extent, modesty (FHI 360, SFH Nigeria, and PSI 2020b). It is interesting to note that while the copper IUD is inserted in a similar fashion, the same concerns about insertion did not emerge as a prominent barrier for copper IUD use. This may reflect differences in the populations of participants who have taken part in research on these two intrauterine methods.

DISCUSSION

The objective of this literature review was to identify enablers and barriers for women’s adoption and continuation of vaginally inserted methods of contraception in LMICs. To our knowledge, this is the first literature review to focus on multiple vaginally inserted methods as the category of inquiry. Previous reviews have limited their focus to specific contraceptive methods (Mishra et al. 2017; Vargas et al. 2019; Gallo, Kilbourne-Brook, and Coffey 2012), other types of method categories, such as LARCs (Coles and Shubkin 2018) or short-acting methods, or specific geographic areas or populations of women (Bain, Amu, and Tarkang 2021).

We found that vaginal insertion—either by the woman herself or a provider—is a barrier to adoption for a minority of women. Only a few of the many studies reviewed found that women were concerned about vaginal insertion, either in terms of discomfort with touching their genitals or concerns about modesty during insertion by a provider. This finding is important because it suggests that some reproductive health experts may have overestimated concerns about vaginal insertion and its impact on the demand for these contraception methods. This finding also complements a wealth of anthropological literature on intravaginal practices, including the insertion of substances into the vagina for a variety of purposes (e.g., cleansing, sexual pleasure, fertility) (Lees et al. 2014; Francis et al. 2012). Additionally, we found that in some cases, discomfort with vaginal self-insertion diminishes over time as women gain more experience and confidence. Furthermore, many women considered a method’s duration of use, including the on demand nature of some vaginal methods, to outweigh their perceived drawbacks.

An acceptable side effect profile, however defined by women, was an enabler to adoption for three of the methods reviewed: the diaphragm, copper IUD and hormonal IUD. Side effects are commonly cited in the broader FP literature as a barrier to contraceptive adoption (Moreira et al. 2019) and continuation (Castle and Askew 2015). By design, vaginally inserted methods do not cause high exposure throughout the body to contraceptive hormones: some are barrier methods without side effects, and others have low systemic effects because of local, steady release of hormones in the vagina or uterus (Hofmann et al. 2020). We found that what is considered acceptable in terms of side effects is a highly individualized calculation of the
benefits and drawbacks of any particular method. For example, reduced menstrual bleeding, a common side effect of the hormonal IUD, was seen as an enabler to use for some women and a barrier for others. We also expect that women’s definitions of an acceptable side effect profile will change as their needs and preferences for contraception evolve over time.

Counseling by a trained provider or community health worker was the most frequently cited enabling factor for adoption of the vaginally inserted methods reviewed. Effective, client-centered counseling can address women’s concerns about trialing vaginally inserted methods, including practicing insertion, alerting women to potential side effects, highlighting important method attributes, countering misconceptions about eligibility and use, and identifying resources to support continued use (or discontinuation and switching, as desired).

There was a widespread lack of awareness about all of the vaginally inserted methods reviewed, which posed a barrier to adoption. It is possible that a lack of awareness among women is linked to provider counseling; providers may not be aware of these methods and, as a result, cannot share information about them with clients. Alternatively, if providers do not have these methods in stock or do not know where they are available for referral, they may choose not to counsel women on them. This situation could change if more vaginally inserted methods are added to FP programs; currently, only three of the five methods (female condoms, copper and hormonal IUDs) are available through UNFPA and USAID. Increasing demand and use of vaginally inserted methods appear to be dependent upon quality provider counseling as well as providers’ readiness and ability to provide products.

Product cost was a major barrier to adoption across all methods. While this barrier is not unique to vaginally inserted methods of contraception, there is a paucity of published resources on the cost of vaginally inserted methods and how they compare to other contraceptive methods. We found that cost was a barrier to adoption in both the private and public sectors, where women can access free or subsidized products but may still be required to pay various user fees (e.g., for insertion or removal). More research is needed on who bears the cost of these methods (e.g., consumers, funders, health systems) as well as practical solutions for decreasing costs to increase women’s access and expand contraceptive choice.

We were surprised by the disparity in the number of studies related to adoption versus continuation. Since women may consider different factors when deciding to adopt or continue using a method, we presented both perspectives. However, more than two-thirds of our findings (and the literature) focused on method adoption. We suspect that the publication disparity could be related to the complexity of measuring contraceptive continuation (e.g., loss to follow-up in longitudinal studies, analytical questions about whether to classify method switchers as discontinuers).

We also noted a disparity in the number of studies that featured different methods. The diaphragm was the least represented in the literature (12 studies included in the analysis), and the copper IUD was the most represented (100 studies included in the analysis). Given the growing attention of the FP community to self-care products that can be used without the support of a provider, we expect more studies about the diaphragm, vaginal ring and female condom to be published in the future.
LIMITATIONS

The results presented in Table 2 and in the method-specific tables provide an overview of the most common enablers and barriers found in the literature on the vaginally inserted methods reviewed. However, the absence of a factor in Table 2 or in the method-specific tables for any particular method should not indicate that it is not relevant but only that it was not among those most frequently cited. In this review, we focused on demand-side enablers and barriers to the adoption and continuation of vaginally inserted methods from the perspective of women and, to a lesser extent, their partners. Although our review concentrates on demand-side factors, we acknowledge that there are a variety of other, complex factors that contribute to method availability (e.g., at the system level, such as regulatory approvals and cost) that program planners and policymakers must take into account. Further research is needed to identify provider and other stakeholder perspectives as well as system-level and supply-side factors that influence adoption and continuation. We did not exclude studies with small sample sizes, which could affect the representativeness of the results. Given the small number of studies for some of the methods, the relative importance of some of the enablers and barriers assessed could be over- or underestimated given the lack of available data. In addition, we did not assess geographic clustering of enablers or barriers—it is likely that some factors are more or less important in different geographies based on culture and context.

CONCLUSION

The results of this review suggest that vaginally inserted methods of contraception play an important role in method offerings by responding to women’s diverse contraceptive needs and preferences. Vaginally inserted methods should not be dismissed outright due to program planners’ or policymakers’ assumptions about demand. Programmatic actions, such as communication activities and quality counseling, can address myths and misconceptions about these methods and contribute to voluntary adoption and continuation. Vaginally inserted methods feature benefits that differ from those of other method options and appeal to a number of women. Women’s contraceptive preferences are diverse: a barrier for some women is an enabler for others. As a result, women require a full suite of choice, including a variety of vaginally inserted methods, to meet their changing needs and preferences over their reproductive lives.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this review are available in the Supporting Information.
REFERENCES

Abdel-Tawab, Nahla G., Shadia Attia, Noourhan Bader, Rania Roushdy, Shatha El-Nakib, and Doaa Oraby. 2020. "Fertility Preferences and Behaviors among Younger Cohorts in Egypt: Recent Trends, Correlates, and Prospects for Change." https://knowledgecommons.popcouncil.org/departments_sbsr-rh/1245/.

Agha, Sohail. 2010. "Intention to Use Contraceptives in Pakistan: Implications for Behavior Change Campaigns." BMCPublic Health 10: 450. https://doi.org/10.1186/1471-2458-10-450

Agot, Kawango, Alexandra M. Minnis, Kghlisho Manenzhe, Erica N. Browne, Khatija Ahmed, Timonthy Okello, and Ariane van der Straten. 2019. "Engaging Study Participants in Interpreting Results: Lessons from the TRIO Study in Kenya and South Africa." International Journal of Women’s Health, 11:395–403. https://doi.org/10.2147/IJWH.S193905.

Ambadekar, N. N., K. Z. Rathod, and Sanjay P. Zodpey. 2010. "Health Care Delivery Practices in the Rural Part of the Yavatmal District Regarding IUD Insertion." Indian Journal of Public Health 54 (4): 201–204. https://doi.org/10.4103/0019-557X.77261.

Animen, Simachew, Selamawit Lake, and Esubalew Mekuriaw. 2018. "Utilization of Intra Uterine Contraceptive Device and Associated Factors among Reproductive Age Group of Family Planning Users in Han Health Center, Bahir Dar, North West Amhara, Ethiopia, 2018." BMC Research Notes 11 (1): 922. https://doi.org/10.1186/s13104-018-4032-z.

Asghar, Samina, Anum Homayun, and Faryal Awan. 2016. "The Future of Postplacental Intrauterine Contraceptive Device (PPIUCD) in Pakistan." Pakistan Journal of Medical and Health Sciences 10 (1): 320–322. https://pjmhsonline.com/2016/jan_mar%20pdf/320%20%20Future%20Postplacental%20Intrauterine%20Contraceptive%20Device%20(PPIUCD)%20Pakistan.pdf

Aung, Tin, May Me Thet, May Sudhinaraset, and Nadia Diamond-Smith. 2019. "Impact of a Social Franchise Intervention Program on the Adoption of Long and Short Acting Family Planning Methods in Hard to Reach Communities in Myanmar." Journal of Public Health (Oxford, England) 41 (1): 192–200. https://doi.org/10.1093/pubmed/fdy005.

Azmat, Syed Khurram, Waqas Hameed, Ghulam Mustafa, Wajahat Hussain, Aftab Ahmed, and Mohsina Bilgrami. 2013. "IUD Discontinuation Rates, Switching Behavior, and User Satisfaction: Findings from a Retrospective Analysis of a Mobile Outreach Service Program in Pakistan." International Journal of Women’s Health 5 (1): 19–27. https://doi.org/10.2147/IJWH. S36785

Azmat, Syed Khurram, Baber Tasneem Shaikh, Waqas Hameed, Mohsina Bilgrami, Ghulam Mustafa, Muhammad Ali, Muhammad Ishaque, Wajahat Hussain, and Aftab Ahmed. 2012. "Rates of IUCD Discontinuation and Its Associated Factors among the Clients of a Social Franchising Network in Pakistan." BMC Women's Health 12:8. https://doi.org/10.1186/1472-6874-12-8.

Bain, Luchuo Engelbert, Hubert Amu, and Elvis Enowbeyang Tarkang. 2021. "Barriers and Motivators of Contraceptive Use among Young People in Sub-Saharan Africa: A Systematic Review of Qualitative Studies." PloS One 16 (6): e0252745. https://doi.org/10.1371/journal.pone.0252745.

Bandura, Albert. 1986. Social Foundations of Thought and Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice-Hall.

Bashi, Yahya H. Dallal, Clare F. McCoy, Diarmuid J. Murphy, Peter Boyd, Patrick Spence, Kyle Kleinbeck, R Karl Malcolm. 2019. "Towards a Dapivirine and Levonorgestrel Multipurpose Vaginal Ring: Investigations into the Reaction between Levonorgestrel and Addition-Cure Silicone Elastomers." International Journal of Pharmaceutics 569 (October): 118574. https://doi.org/10.1016/j.ijpharm.2019.118574.

Beksinska, Mags, Ross Greener, Jenni Smit, Busi Maphumulo, Nonhlanhla Mphili, Maggie Kilbourne-Brook, and Patricia S. Coffey. 2018. "A Randomized Crossover Study Evaluating the Use and Acceptability of the SILCS Diaphragm Compared to Vaginal Applicators for Vaginal Gel Delivery." AIDS and Behavior 22 (1): 127–132. https://doi.org/10.1007/s10461-017-1913-4.

Beksinska, Mags, Phumla Nkosi, Zonke Mabude, Joanne E. Mantell, Bongiwe Zulu, Cecilia Milford, and Jennifer A. Smit. 2020. "Lessons from the Evaluation of the South African National Female Condom Programme." PloS One 15 (8): e0236984. https://doi.org/10.1371/journal.pone.0236984.

Beksinska, Mags, Jennifer Smit, Nonhlanhla Mphili, Ross Greener, and Virginia Maphumulo. 2019. "The Panty Condom: A Pilot Study of the Function and Acceptability of an Alternative Female Condom Design." International Journal of STD and AIDS 30 (11):1080–1086. https://doi.org/10.1177/0956462419845543.

Bertrand, Jane T., John Ross, Tara M. Sullivan, Karen Hardee, and James D. Shelton. 2020. "Contraceptive Method Mix: Updates and Implications." Global Health: Science and Practice 8 (4): 666–679. https://doi.org/10.9745/GHSP-D-20-00229.
Barriers and Enablers to Use of Vaginally Inserted Contraceptive Methods

Bharadwaj, Meenakshi Kanwar. 2015. “Contraceptive Acceptability of Female Condom: A Prospective Study.” *Journal of SAFOG* 7 (1): 10–14. https://doi.org/10.5005/jp-journals-10006-1312.

Blumenthal, Paul D., Nirali M. Chakraborty, Sarah Prager, Pratima Gupta, Klaira Lerma, and Bellington Wvalika. 2016. “Programmatic Experience of Post-Partum IUD Use in Zambia: An Observational Study on Continuation and Satisfaction.” *European Journal of Contraception and Reproductive Health Care* 21 (5): 356–360. https://doi.org/10.1080/13625187.2016.1201655.

Hofmann, Birte Maria, Dan Apter, Johannes Bitzer, Isabel Reinecke, Marco Serrani, Joachim Höchel, and Martin Merz. 2020. “Comparative Pharmacokinetic Analysis of Levonorgestrel-Releasing Intrauterine Systems and Levonorgestrel-Containing Contraceptives with Oral or Subdermal Administration Route.” *The European Journal of Contraception & Reproductive Health Care* 25 (6): 417–426. https://doi.org/10.1080/13625187.2020.1815008.

Boller, Marie, Meredith Jean-Baptiste, Christophe Millicen, Theophile Renise, and Marisa Nádas. 2018. “Perceptions of Intra-Uterine Device Users in Mirebalais, Haiti: A Mixed Methods Study.” *Annals of Global Health* 84 (4): 663–669. https://doi.org/10.29024/aogh.2375.

Bulto, Gizachew Abdissa, Tatek Abate Zewdie, and Teresa Kisi Beyen. 2014. “Demand for Long Acting and Permanent Contraceptive Methods and Associated Factors among Married Women of Reproductive Age Group in Debre Markos Town, North West Ethiopia.” *BMC Women's Health* 14 (1): 46. https://doi.org/10.1186/1472-6874-14-46.

Castles, Sarah, Heidi Schroffel, Jean Jose Nzau Mvuezolo, Bavon Mupenda, Justin Mumbere, and Rachel Shapiro. 2019. “Successful Programmatic Approaches to Facilitating IUD Uptake: CARE's Experience in DRC.” *BMC Women's Health* 19 (1): 104. https://doi.org/10.1186/s12905-019-0793-3.

Castle, Sarah, and Ian Askew. 2015. “Contraceptive Discontinuation: Reasons, Challenges and Solutions.” http://ec2-54-210-230-186.compute-1.amazonaws.com/wp-content/uploads/2015/12/FP2020_ContraceptiveDiscontinuation_SinglePage_Final_12.08.15.pdf.

Cervical Barrier Advancement Society. 2022. “Diaphragms.” https://cervicalbarriers.org/diaphragms/.

Chippuwa, Tirivanhu, Ancia Manwere, Margret M. Kuchenga, Lynah Makuyana, Estelle Mwanza, Elizabeth Makado, and Rumbidzai P. Chimutso. 2014. “Level of Awareness and Uptake of the Female Condom in Women Aged 18 to 49 Years in Bindura District, Mashonaland Central Province, Zimbabwe.” *African Journal of AIDS Research* 13 (1): 75–80. https://doi.org/10.2989/16085906.2014.901979.

Coffey, Patricia S., and Maggie Kilbourne-Brook. 2010. “Wear and Care of the SILCS Diaphragm: Experience from Three Countries.” *Sexual Health* 7 (2): 159–164. https://doi.org/10.1071/SH09049.

Coffey, Patricia S., Maggie Kilbourne-Brook, Wu Junqing, Zhang Yufeng, Zhao Hongxin, Wen Bin, Li Na, Zhao Rui, Li Yuyan. 2013. “Initial Reactions to the Woman's Condom by Potential User Groups in Shanghai, China.” *Journal of Family Planning and Reproductive Health Care* 39 (2): 111–120. https://doi.org/10.1136/jfprhc-2011-100211.

Coles, Chelsey B., and Catherine D. Shubkin. 2018. “Effective, Recommended, Underutilized: A Review of the Literature on Barriers to Adolescent Usage of Long-Acting Reversible Contraceptive Methods.” *Current Opinion in Pediatrics* 30 (5): 683–688. https://doi.org/10.1097/MOP.0000000000000663.

Da Costa, Vanessa, Rosine Ingabire, Robertine Sinabamwe, Etienne Karita, Victoria Umutoni, Alexandra Hoagland, Susan Allen, Ellen Mork, Rachel Parker, Jeannine Mukamuyango, Lisa Haddad, Julien Nyombayire, Kristin M. Wall. 2019. “An Exploratory Analysis of Factors Associated With Interest in Postpartum Intrauterine Device Uptake Among Pregnant Women and Couples in Kigali, Rwanda.” *Clinical Medicine Insights: Reproductive Health* 13: 1–11. https://doi.org/10.1177/1179558119886843.
Dam, Purvita, Joydip Paul, Indranil Banerjee, Ashima Sorkhel, and Partha Sarathi Chakravorty. 2015. "To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women." Journal of Evolution of Medical and Dental Sciences 4 (38): 6602–6612. https://doi.org/10.14260/jemds/2015/956.

Danna, Kendal, Ashley Jackson, Chastain Mann, and Danielle Harris. 2019. "Expanding Effective Contraceptive Options: Lessons Learned from the Introduction of the Levonorgestrel Intrauterine System (LNG-IUS) in Zambia and Madagascar." WCG Cares. http://www.wcgcares.org/wp-content/uploads/2019/04/ECCO-LNG-IUS-Case-Study.pdf.

Das, Sourav, Ashima Sanyal, Rajib Roy, Pallab Mistri, Manisha Vernekar, and Tapan Kumar Naskar. 2016. "Combined Contraceptive Vaginal Ring- Its Acceptability in Indian Women." Indian Journal of Public Health Research and Development 7 (1): 57–63. https://doi.org/10.5958/0976-5506.2016.00012.7.

Das, Udita, Mamta Sharma, Maggie Kilbourne-Brook, and Patricia S. Coffey. 2015. "Exploring Vaginal Ring Acceptability for Contraception and Sexually Transmissible Infection Protection in India: A Qualitative Research Study." Sexual Health 12 (6): 532–540. https://doi.org/10.1071/SH15071.

Davidson, Autumn S., Camille Fabiyi, Shiferaw Demissie, Hiwot Getachew, and Melissa L. Gilliam. 2017. "Is LARC for Everyone? A Qualitative Study of Sociocultural Perceptions of Family Planning and Contraception Among Refugees in Ethiopia." Maternal and Child Health Journal 21(9):1699–1705. https://doi.org/10.1007/s10995-016-2018-9.

Dereje, Nebiyu, Biruk Engida, and Roger P. Holland. 2020. "Factors Associated with Intrauterine Contraceptive Device Use among Women of Reproductive Age Group in Addis Ababa, Ethiopia: A Case Control Study." PloS One 15 (2): e0229071. https://doi.org/10.1371/journal.pone.0229071.

Divakar, Hema, Ajeay Bhardwaj, Chittaranjan N. Purandare, Thelma Sequeira, and Pooja Sanghvi. 2019. "Critical Factors Influencing the Acceptability of Post-Placental Insertion of Intrauterine Contraceptive Device: A Study in Six Public/Private Institutions in India." Journal of Obstetrics and Gynecology of India 69 (4): 344–349. https://doi.org/10.1007/s13224-019-01221-7.

Eliason, Sebastian, Frank Baiden, Gloria Quansah-Asare, Yvonne Graham-Hayfron, Derek Bonsu, James Phillips, and Kofi Awusubo-Asare. 2013. "Factors Influencing the Intentation of Women in Rural Ghana to Adopt Postpartum Family Planning." Reproductive Health 10 (34). https://doi.org/10.1186/1742-4755-10-34.

Elkhateeb, Reham Refaat, Eman Kishk, Ahmad Sanad, Haitham Bahaa, Abdel Rahman Hagaazy, Kareem Shaheen, Enas Moustafa, Hahem Fares, Khalid Gomaa, and Ahmad Mahran. 2020. "The Acceptability of Using IUDs among Egyptian Nulliparous Women: A Cross-Sectional Study." BMC Women’s Health 20 (117). https://doi.org/10.1186/s12905-020-00977-9.

Eluwa, George IE, Ronke Atamewalen, Kingsley Odogwu, and Babatunde Ahonsi. 2016. "Success Providing Postpartum Intrauterine Devices in Private-Sector Health Care Facilities in Nigeria: Factors Associated With Uptake." Global Health: Science and Practice 4 (2): 276–283. https://doi.org/10.9745/GHSP-D-16-00072.

Enyindah, C.E., John D. Ojule, and Goddy Bassey. 2012. "Contraception with Intrauterine Contraceptive Device (IUCD) in Port Harcourt, South-South Nigeria." Journal of Medicine and Biomedical Research 11 (1): 35–45. https://www.ajol.info/index.php/jmbr/article/view/81355.

Eshak, Ehab. 2020. "Myths about Modern and Traditional Contraceptives Held by Women in Minia, Upper Egypt.” Eastern Mediterranean Health Journal 26 (4): 417–425. https://doi.org/10.26719/emhj.19.053.

Eva, Gillian, Geeta Nanda, Kate Rademacher, Anna Mackay, Omaye Negedu, Anne Taiwo, Leila Dal Santo, Mariya Saleh, Lucky Palmer, Tracey Brett. 2018. "Experiences with the Levonorgestrel Intrauterine System Among Clients, Providers, and Key Opinion Leaders: A Mixed-Methods Study in Nigeria." Global Health, Science and Practice 6 (4): 680–692. https://doi.org/10.9745/GHSP-D-18-00242.

Ezegwui, Hyginus, E.E. Nwogu-Ikojo, Lawrence Chigbata Ikeako, and Sylvester Nweze. 2013. "Trend in the Use of Intra-Uterine Contraceptive Device (IUCD,TCU 380A), in Enugu, Nigeria." Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria 22 (3): 193–197. https://pubmed.ncbi.nlm.nih.gov/24180146/.

Ezegwui, Ezebuzo C., John I. Achara, Onyinye C. Ezegwui, and Hyginus U. Ezegwui. 2020. "Acceptance of Postpartum Intrauterine Contraceptive Device among Women Attending Antenatal Care in a Low-Resource Setting in Nigeria." International Journal of Gynecology and Obstetrics 148 (2): 181–186. https://doi.org/10.1002/ijgo.13027.

Family Planning (FP) 2020. 2021. "Introduction of Long-Acting Family Planning Method to USAID and UNFPA Product Catalogs." https://familyplanning2020.org/news/introduction-long-acting-family-planning-method-usaid-and-unfpa-product-catalogs.
FHI 360. 1995. “Intrauterine Devices (IUDs).” Accessed August 19, 2021. https://www.fhi360.org/sites/default/files/webpages/Modules/IUD/s1pg8.htm

FHI 360. 2012. “Postpartum Family Planning: New Research Findings and Program Implications.” https://www.fhi360.org/sites/default/files/media/documents/Postpartum%20Family%20Planning.pdf

FHI 360. 2014. “Contextual Barriers and Coping Strategies for Uptake of Modern Contraceptive Services and Commodities in a Selected Community in Uganda: Highlights from a Rapid Qualitative Assessment.” https://www.fhi360.org/sites/default/files/media/documents/Modern-Contraceptive-Services-Uganda-Qualitative-Assessment-FINAL%20.pdf

FHI 360. 2017. “Final Report: User Perspectives on New Long-Acting Contraceptive Technologies.” https://www.fhi360.org/sites/default/files/media/documents/resource-user-preferences-lac.pdf

FHI360 and Family Health Options Kenya. 2016. “Final Report: Qualitative Interviews with Mirena Users and Their Partners in Kenya.” https://6dc13253-8668-46dc-80d3-a17a285a56f3.filesusr.com/ugd/3c50c1_f74dbd2da7bb4f06ba0880254f3cf946.pdf

FHI 360, Society for Family Health (SFH) Nigeria, PSI. 2020a. “LEAP Initiative: A Mixed Method, Longitudinal Study in Nigeria.” https://6dc13253-8668-46dc-80d3-a17a285a56f3.filesusr.com/ugd/3c50c1_8f842384e10649f5d1ebdd39729300.pdf

FHI 360, SFH Nigeria, PSI. 2020b. “LEAP Initiative: Adolescent Girls’ and Young Women’s Perspectives on the LNG IUS in Nigeria.” https://6dc13253-8668-46dc-80d3-a17a285a56f3.filesusr.com/ugd/3c50c1_220e4d36d54a54587b53ff7a7d29cd84e.pdf

Fishbein, Martin, and Marco C. Yzer. 2003. “Using Theory to Design Effective Health Behavior Interventions.” Communication Theory 13 (2): 164–183. https://doi.org/10.1111/j.1468-2885.2003.tb00287.x

Francis, Suzanna C., Shelley S. Lees, Bahati Andrew, Flavia zalwango, Judith Vandepitte, Trong Ao, Kathy Baisley, Saidi Kapiga, Heiner Grosskurth, Richard Hayes. 2012. “Vaginal Practices Diary: Development of a Pictorial Data Collection Tool for Sensitive Behavioural Data.” Sexually Transmitted Diseases 39 (8): 614–621. https://doi.org/10.1097/OLQ.0b013e3182515fe4.

Gallo, Maria F., Maggie Kilbourne-Brook, and Patricia S. Coffey. 2012. “A Review of the Effectiveness and Acceptability of the Female Condom for Dual Protection.” Sexual Health 9 (1): 18–26. https://doi.org/10.1071/SH11037.

Gambir, Katherine, Jessica Pinchoff, Olasubomi Obadeyi, and Thoai D. Ngo. 2019. “Opportunities and Challenges for the Introduction of a New Female Condom among Young Adults in Urban Zambia.” Reproductive Health 16 (1): 175. https://doi.org/10.1186/s12978-019-0839-x.

Gedeon, Jillian, Saw Nanda Hseue, Meredith Walsh, Cari Sietstra, Hay MarSan, and Angel M. Foster. 2015. “Assessing the Experiences of Intra-Uterine Device Users in a Long-Term Conflict Setting: A Qualitative Study on the Thailand-Burma Border.” Conflict and Health 9 (6). https://doi.org/10.1186/s13031-015-0034-9.

Gollub, Erica L. 2000. “The Female Condom: Tool for Women’s Empowerment.” American Journal of Public Health 90 (9): 1377–1381. https://doi.org/10.2105/ajph.90.9.1377.

Gomez, Anabel, Chastain Mann, Temple Cooley, and Nora Miller. 2018. “Expanding Effective Contraceptive Options in Zambia and Malawi: Understanding the Consumer.” WCG Cares. https://www.psi.org/wp-content/uploads/2020/02/EECO-Case-Study-1-Zambia-Malawi_Final-for-web.pdf

Goswami, Gunjan, Kalpana Yadav, and Ankita Patel. 2015. “A Prospective Study to Evaluate Safety, Efficacy and Expulsion Rate of Post-Placental Insertion of Intra Uterine Device.” Journal of Evolution of Medical and Dental Sciences 4 (56): 9770–9774. https://doi.org/10.14260/jemds/2015/1410.

Gottert, Ann, Karin Jacquin, Bakoly Rahavondrafahitra, Kathryn Moracco, and Suzanne Maman. 2015. “Influences on Women’s Decision Making about Intrauterine Device Use in Madagascar.” Contraception 91 (4): 289–294. https://doi.org/10.1016/j.contraception.2015.01.014.

Gutin, Sarah A., Regina Mlobeli, Margaret Moss, Geoffrey Buga, and Chelsea Morroni. 2011. “Survey of Knowledge, Attitudes and Practices Surrounding the Intrauterine Device in South Africa.” Contraception 83 (2): 145–150. https://doi.org/10.1016/j.contraception.2010.07.009.

Hameed, Waqas, Syed K. Azmat, Muhammad Ishaque, Wajahat Hussain, Erik Munroe, Gulam Mustafa, Omar Farooq Khan, Ghazunfer Abbas, Saifar Ali, Qaiser Jamshaid Asghar, Saif Ali, Aftab Ahmed, and Hasan Bin Hamza. 2015. “Continuation Rates and Reasons for Discontinuation of Intra-Uterine Device in Three Provinces of Pakistan: Results of a 24-
Danielle M. Harris et al.

Month Prospective Client Follow-Up.” *Health Research Policy and Systems* 13 (Suppl. 1): 53. https://doi.org/10.1186/s12961-015-0040-9.

Harris, Danielle, and Alexandra Angel. 2020. ”Expanding Effective Contraceptive Options: Introducing the Caya Diaphragm in Niger.” WCG Cares. http://wgc cares.org/wp-content/uploads/2020/07/EECO-Caya-Intro-in-Niger_June-2020.pdf.

Hayes, Janie, and Maggie Kilbourne-Brook. 2016a. “Feasibility of SILCS Introduction in South Africa.” PATH. https://path.azureedge.net/media/documents/DT_silcs_hsa_sa_br.pdf.

Hayes, Janie, and Maggie Kilbourne-Brook. 2016b. “Feasibility of SILCS Introduction in Uganda.” PATH. https://path.azureedge.net/media/documents/DT_silcs_hsa_uganda_br.pdf.

Hemmerling, Anke, Emily Christopher, and Bethany Young Holt. 2020. ”Towards a Roadmap to Advance Non-Hormonal Contraceptive Multipurpose Prevention Technologies: Strategic Insights from Key Stakeholders.” *Biology of Reproduction* 103 (2): 289–298. https://doi.org/10.1093/biolre/ioaa092.

Heuvel, Michiel Wilhelmus van den, Antoinetta Jacoba Maria van Bragt, Ali Kafi Mohammed Alnabawy, and Marc Carel John Kaptein. 2005. ”Comparison of Ethinylestradiol Pharmacokinetics in Three Hormonal Contraceptive Formulations: The Vaginal Ring, the Transdermal Patch and an Oral Contraceptive.” *Contraception* 72 (3): 168–174. https://doi.org/10.1016/j.contraception.2005.03.005.

Ho, Lara S., and Erin Wheeler. 2018. ”Using Program Data to Improve Access to Family Planning and Enhance the Method Mix in Conflict-Affected Areas of the Democratic Republic of the Congo.” *Global Health: Science and Practice* 6 (1): 161–177. https://doi.org/10.9745/GHSP-D-17-00365.

Huber-Krum, Sarah, Kristy Hackett, Leigh Senderowicz, Erin Pearson, Joel M. Francis, Hellen Siril, Nzoov Ulena, and Iqbal Shah. 2019. ”Women’s Perspectives on Postpartum Intrauterine Devices in Tanzania.” *Studies in Family Planning* 50 (4): 317–336. https://doi.org/10.1111/sifp.12106.

Huda, Fauzia Akhter, Sabiha Chowdhuri, Bidhan Sarker, Noushin Islam, and Anisuddin Ahmed. 2014. ”Prevalence of Unintended Pregnancy and Needs for Family Planning among Married Adolescent Girls Living in Urban Slums of Dhaka, Bangladesh.” *Population Council*. https://doi.org/10.31899/rh4.1050.

Husain, Sonia, Samia Husain, and Rubina Izhar. 2019. ”Women’s Decision versus Couples’ Decision on Using Postpartum Intra-Uterine Contraceptives.” *Eastern Mediterranean Health Journal* 25 (5): 322–330. https://doi.org/10.26719/emhj.18.043.

Jairaj, Sangeetha, and Sridhar Dayyala. 2016. ”A Cross Sectional Study on Acceptability and Safety of IUCD among Postpartum Mothers at Tertiary Care Hospital, Telangan.” *Journal of Clinical and Diagnostic Research* 10 (1): LC01–LC04. https://doi.org/10.7860/JCDR/2016/16871.7020.

Joanis, Carol, Mags Bekinska, Catherine Hart, Katie Tweedy, Jabu Linda, and Jenni Smit. 2011. ”Three New Female Condoms: Which Do South-African Women Prefer?” *Contraception* 83 (3): 248–254. https://doi.org/10.1016/j.contraception.2010.08.002.

Kakaire, Othman, Nazarius M. Tumwesigye, Josaphat K. Byamugisha, and Kristina Gemzell-Danielsson. 2016. ”Acceptability of Intrauterine Contraception among Women Living with Human Immunodeficiency Virus: A Randomised Clinical Trial.” *European Journal of Contraception and Reproductive Health Care* 21 (3): 220–226. https://doi.org/10.3109/13625187.2016.1146249.

Kanda, Luhaka, and Robert Mash. 2018. ”Reasons for Inconsistent Condom Use by Young Adults in Mahalapye, Botswana.” *African Journal of Primary Health Care & Family Medicine* 10 (1). https://doi.org/10.4018/phcfm.v10i1l.1492.

Karra, Mahesh, David Canning, Sorcha Foster, Iqbal H. Shah, Hemantha Senanayake, U.D.P. Ratnasiri, and Ramya P. Pathiraja. 2017. ”Location and Content of Counselling and Acceptance of Postpartum IUD in Sri Lanka.” *Reproductive Health* 14 (42). https://doi.org/10.1186/s12978-017-0304-7.

Karra, Mahesh, Erin Pearson, Elina Pradhan, Ranjith De Silva, Arnjali Samarasekera, David Canning, Iqbal Shah, Deepal Weerasekera, and Hemantha Senanayake. 2019. ”The Effect of a Postpartum IUD Intervention on Counseling and Choice: Evidence from a Cluster-Randomized Stepped-Wedge Trial in Sri Lanka.” *Trials* 20 (407). https://doi.org/10.1186/s13063-019-3473-6.

---

Studies in Family Planning 53(3) September 2022
Kathpalia, Brig S.K., and Lt Col M.S. Mustafa. 2015. "Awareness about Postpartum Insertion of Intrauterine Device among Antenatal Cases." *Medical Journal Armed Forces India* 71 (3): 221–224. https://doi.org/10.1016/j.mjafi.2015.04.002.

Kestelyn, Evelyne, Jennifer Ilo Van Nuil, Marie M. Umulis, Grace Umutoni, Alice Uvingabire, Lambert Mwambangwwe, Mireille Uwineza, Stephen Agaba, Tania Crucitti, Janneke van de Wijgert, Thérèse Delvaux, and for the Ring Plus Study Group. 2018. "High Acceptability of a Contraceptive Vaginal Ring among Women in Kigali, Rwanda." *PloS One* 13 (6): e0199096. https://doi.org/10.1371/journal.pone.0199096.

Kestelyn, Evelyne, Stephen Agaba, Jennifer Ilo Van Nuil, Mireille Uwineza, Marie Michelle Umulis, Lambert Mwambangwwe, Jean Claude Ndajjijjuma, Irith De Baetselier, Jozefien Buyze, Thérèse Delvaux, Tania Crucitti, Vicky Jespers, Janneke H. H. M. van de Wijgert, and the Ring Plus Study Group. 2018. "A Randomised Trial of a Contraceptive Vaginal Ring in Women at Risk of HIV Infection in Rwanda: Safety of Intermittent and Continuous Use." *PloS One* 13 (6): e0197572. https://doi.org/10.1371/journal.pone.0197572.

Khan, Aamina, and Babar T. Shaikh. 2013. "An All Time Low Utilization of Intrauterine Contraceptive Device as a Birth Spacing Method: A Qualitative Descriptive Study in District Rawalpindi, Pakistan." *Reproductive Health* 10 (10). https://doi.org/10.1186/1742-4755-10-10.

Khatrì, Bijay, Anjana Khadka, Archana Amatya, Sushan Man Shrestha, and Rajan Paudel. 2019. "Perception and Use of Intrauterine Contraceptive Devices (IUCD) among Married Women Of Reproductive Age In Bhaktapur, Nepal." *Open Access Journal of Contraception* 2019 (10): 69–77. https://doi.org/10.2147/OAJC.S219888.

Kumar, Avinash, Anam A. Alwani, R. Unnikrishnan, Rekha Thapar, Prasanna Mithra, Nithin Kumar, Vaman Kulkarni, and Ramesh Holla. 2018. "Determinants of Intrauterine Device Acceptance among Married Women in Coastal Karnataka, India." *Journal of Clinical and Diagnostic Research* 12 (6): LC05–LC09. https://doi.org/10.7860/JCRD/2018/34146.11637.

Kumar, Somesh, Ashish Srivastava, Surendra Sharma, Vivek Yadav, Atul Mittal, Young-Mi Kim, Angela Nash-Mercado, Sijmen A Reijneveld, Bulbul Sood. 2019. "One-Year Continuation of Postpartum Intrauterine Contraceptive Device: Findings from a Retrospective Cohort Study in India." *Contraception* 99 (4): 212–216. https://doi.org/10.1016/j.contraception.2018.12.003.

Kumar, Somesh, Reena Sethi, Sudharsanam Balasubramaniam, Elaine Charurat, Kamlesh Lachhandani, Richard Semba, and Bulbul Sood. 2014. "Women’s Experience with Postpartum Intrauterine Contraceptive Device Use in India." *Reproductive Health* 11(32). https://doi.org/10.1186/1742-4755-11-32.

Kwamwanga, Imelda T., Eleanor Turyakira, Maggie Kilbourne-Brook, and Patricia S. Coffey. 2014. "Potential for Revitalisation of the Diaphragm for Family Planning in Uganda: A Rapid Assessment of the Feasibility of Introducing the SILCS Diaphragm." *African Journal of Reproductive Health* 18 (2): 77–86. https://pubmed.ncbi.nlm.nih.gov/25022144/.

LaMorte, Wayne W. 2019. "The Transtheoretical Model (Stages of Change)." *Boston University School of Public Health.* https://tinyurl.com/mpj8d7fc.

Landolt, Nadia K., Nittaya Phanuphak, Nipat Teeratakulpisarn, Rosalin Kriengsinyot, Jennisa Ahluwalia, Suteeraporn Pinyakorn, Surasith Chaithongwongwatthana, and Jintanat Ananworanich. 2013. "Uptake and Continuous Use of Copper Intrauterine Device in a Cohort of HIV-Positive Women." *AIDS Care* 25 (6): 710–714. https://doi.org/10.1080/09540121.2012.752786.

Latka, Mary. 2001. "Female-Initiated Barrier Methods for the Prevention of STI/HIV: Where Are We Now? Where Should We Go?" *Journal of Urban Health* 78 (4): 571–580. https://doi.org/10.1093/jurban/78.4.571.

Lees, Shelley, Flavia Zalwango, Bahati Andrew, Judith Vandepitte, Janet Seeley, Richard J. Hayes, and Suzanna C. Francis. 2014. "Understanding Motives for Intravaginal Practices amongst Tanzanian and Ugandan Women at High Risk of HIV Infection: The Embodiment of Social and Cultural Norms and Well-Being." *Social Science & Medicine* 102 (February): 165–173. https://doi.org/10.1016/j.socscimed.2013.12.005.

Liambila, Wilson, Deepa Rajamani, Francis Obare, Saumya RamaRao, Harriet Birungi, and Heather Clark. 2015. "Willingness to Pay for Contraceptive Vaginal Rings in Kenya." The Population Council. https://knowledgecommons.popcouncil.org/cgi/viewcontent.cgi?article=1719&context=departments_sbsr-rh.

Luo, Zhongchen, Lingling Gao, Ronald Anguzu, and Juanjuan Zhao. 2018. "Long-Acting Reversible Contraceptive Use in the Post-Abortion Period among Women Seeking Abortion in Mainland China: Intentions and Barriers." *Reproductive Health* 15 (85). https://doi.org/10.1186/s12978-018-0543-2.

Machado, Rogério Bonassi, Luciano Melo Pompei, Arícia Giribela, and Nilson Roberto de Melo. 2013. "Impact of Standardized Information Provided by Gynecologists on Women’s Choice of Combined Hormonal Contraception."
Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology 29 (9): 855–858. https://doi.org/10.3109/09513590.2013.808325.

Mack, Natasha, Thomas G. Grey, Alexis Amsterdam, Claudia Interiano Matta, and Nancy Williamson. 2010. "Central American Sex Workers’ Introduction of the Female Condom to Different Types of Sexual Partners." AIDS Education and Prevention 22 (5): 466–481. https://doi.org/10.1521/acep.2010.22.5.466.

Mack, Natasha, Thomas G. Grey, Alexis Amsterdam, Nancy Williamson, and Claudia Interiano Matta. 2010. "Introducing Female Condoms to Female Sex Workers in Central America." International Perspectives on Sexual and Reproductive Health 36 (3): 149–155. https://doi.org/10.1363/ipsrh.36.149.10.

Mahlalela, Nomsa Brightness, and Pranitha Maharaj. 2015. "Factors Facilitating and Inhibiting the Use of Female Condoms among Female University Students in Durban, KwaZulu-Natal, South Africa." European Journal of Contraception and Reproductive Health Care 20 (5): 379–386. https://doi.org/10.1039/s13625317.2015.1036415.

Malik, Roopa, Vijayata Sangwan, Smiti Nanda, Viral Kumar, and Mukesh Kumar. 2014. "Discontinuation Pattern among IUCD Users: A Study at Tertiary Health Care Centre." Journal of South Asian Federation of Obstetrics and Gynaecology 6 (1): 8–10. https://doi.org/10.5005/jp-journals-10006-1257.

Mantell, Joanne E., Theresa M. Exner, Dan Bai, Cheng-Shiun Leu, Mags Beksinska, Zonke Mabude, Susie Hoffman, and Jennifer A. Smit. 2020. "Perceived Male Partner Attitudes toward the Female Condom Predict Female University Students’ Use of the Female Condom." International Journal of Gynecology and Obstetrics 143 (Suppl. 1): 13–19. https://doi.org/10.1002/ijgo.12599.

Marston, Cicely, Alicia Renedo, Gertrude Nyaaba, Kazuyo Machiyama, and Placide Tapsoba. 2016. "Understanding Fertility Regulation Strategies among Educated Women in Accra." Population Council. https://doi.org/10.3189/9rh4.1037.

Martin, Julia, Patsy de Lora, Roger Rochat, and Karen L. Andes. 2016. "Understanding Female Condom Use and Negotiation among Young Women in Cape Town, South Africa." International Perspectives on Sexual and Reproductive Health 42 (1): 13–20. https://doi.org/10.1363/42e0216.

Masvawure, Tsitsi B., Joanne E. Mantell, Zonke Mabude, Claudia Ngoloyi, Cecilia Milford, Mags Beksinska, and Jennifer A. Smit. 2014. “‘It’s a Different Condom, Let’s See How It Works’: Young Men’s Reactions to and Experiences of Female Condom Use during an Intervention Trial in South Africa.” Journal of Sex Research 51 (8): 841–851. https://doi.org/10.1080/00224499.2013.814043.

Maternal and Child Survival Program (MCSP). 2019. "Incorporating the Hormonal Intrauterine System into the Contraceptive Method Mix in the Public Health Sector in Zambia." https://www.mcsprogram.org/wp-content/uploads/2020/05/2_MCSP-Zambia-Hormonal-IUS-Learning-Brief-Final.pdf.

Mathenjwa, Thulile, and Pranitha Maharaj. 2012. "Female Condoms Give Women Greater Control’: A Qualitative Assessment of the Experiences of Commercial Sex Workers in Swaziland.” European Journal of Contraception and Reproductive Health Care 17 (5): 383–392. https://doi.org/10.3109/13625187.2012.694147.

Mazzei, Rosine Ingabire, Jeannine Mukumuyango, Julien Nyombayire, Robertine Sinabamenye, Roger Bayingana, Rachel Parker, Amanda Tichacek, Sarah Rae Easter, Etienne Karita, Susan Allen, and Kristin M. Wall. 2019. “Community Health Worker Promotions Increase Uptake of Long-Acting Reversible Contraception in Rwanda.” Reproductive Health 16 (75). https://doi.org/10.1186/s12978-019-0739-0.

McDonald-Mosley, Raegan, Kameelah Philips, Lauren Ditizian, and Miriam Cremer. 2010. "Acceptability of the Intrauterine Device among Women in El Salvador." International Journal of Gynecology and Obstetrics 108 (2): 155–157. https://doi.org/10.1016/j.ijgo.2009.09.016.

Mekonnen, Getachew, Fikre Enquselassie, Gezahgn Tesfaye, and Agumasi Semachegn. 2014. "Prevalence and Factors Affecting Use of Long Acting and Permanent Contraceptive Methods in Jinka Town, Southern Ethiopia: A Cross Sectional Study." The Pan African Medical Journal 18 (98). https://doi.org/10.11604/pamj.2014.18.98.3421.

Miller, Nora, Chastain Mann, Ashley Jackson, and Danielle Harris. 2018. "Expanding Effective Contraceptive Options: Lessons Learned from the Woman’s Condom Introduction in Zambia and Malawi." WCG Cares. https://marketbookshelf.com/wp-content/uploads/2019/02/EECO-Womans-Condoms-Condom-Lessons-Learned.pdf.
Barriers and Enablers to Use of Vaginally Inserted Contraceptive Methods

Minnis, Alexandra M., Sarah T. Roberts, Kawango Agot, Rachel Weinrib, Khatija Ahmed, Kgahliso Manenzhe, Fredrick Owino. 2018. “Young Women’s Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.” AIDS and Behavior 22: 2662–2673. https://doi.org/10.1007/s10461-018-2078-5.

Mishra, Namita, Meely Panda, Souvik Pyne, Nallala Srinivas, Sandipana Pati, and Sanghamitra Pati. 2017. “Barriers and Enablers to Adoption of Intrauterine Device as a Contraceptive Method: A Multi-Stakeholder Perspective.” Journal of Family Medicine and Primary Care 6 (3): 616–621. https://doi.org/10.4103/2249-4863.222028.

Moagi, M.E., Leon C. Smyn, and Jennifer D. Makin. 2019. “Feasibility and Uptake of Intrauterine Contraceptive Device at the Time of Uterine Evacuation in Women Presenting with Incomplete miscarriage at Kalafong Provincial Tertiary Hospital.” Obstetrics and Gynecology Forum 29 (2): 24–26. https://repository.up.ac.za/handle/2263/71266.

Mokgetse, Moitlamo, and Mokholelana M. Ramukumba. 2018. “Female Condom Acceptability and Use amongst Young Women in Botswana.” Curationis 41 (1): e1–e6. https://doi.org/10.4102/curationis.v41i1.1887.

Monji Builu, Pierre, and Thinagrin Dhasarathun Naidoo. 2015. “Attitudes towards and Knowledge about Intrauterine Contraceptive Devices among Women in the Reproductive Age Group in a Resource-Constrained Setting.” South African Journal of Obstetrics and Gynaecology 21 (2): 27–32. https://doi.org/10.7196/SAJOG.950.

Moreira, Laísa Rodrigues, Fernanda Ewerling, Aluisio J. D. Barros, and Mariangela Freitas Silveira. 2019. “Reasons for Nonuse of Contraceptive Methods by Women with Demand for Contraception Not Satisfied: An Assessment of Low and Middle-Income Countries Using Demographic and Health Surveys.” Reproductive Health 16 (1): 148. https://doi.org/10.1186/s12978-019-0805-7.

Morineau, Guy. 2011. “Behaviors, Knowledge, Exposure to Interventions: Report from a Behavioral Surveillance Survey (Port Moresby, Papua New Guinea).” FHI360. https://www.fhi360.org/sites/default/files/media/documents/BSSPNGReportFinal2011.pdf.

Naidu, Maheshvari. 2013. “Perceptions around Second Generation Female Condoms: Reporting on Women’s Experiences.” Anthropological Notebooks 19 (1): 25–34. https://researchspace.ukzn.ac.za/handle/10413/9935.

Nanda, Geeta, Kate Rademacher, Marsden Solomon, Sarah Mercer, Jim Wawire, and Rose Ngahu. 2018. “Experiences with the Levonorgestrel-Releasing Intrauterine System in Kenya: Qualitative Interviews with Users and Their Partners.” European Journal of Contraception and Reproductive Health Care 23 (4): 303–308. https://doi.org/10.1080/13665187.2018.1499892.

Ndegwa, Serah Wanjiro, Joseph W. Gichuhi, Zahida Qureshi, and Kizito Lubano. 2014. “The Effect of Two Levels of Counselling on Acceptance, Uptake and Early Outcomes of Post-Placental Intra-Uterine Contraceptive Device.” East African Medical Journal 91 (12): 449–456. https://pubmed.ncbi.nlm.nih.gov/26859013/.

Nigam, Aruna, Ayesha Ahmad, Anshu Sharma, Poonam Saith, and Swaraj Batra. 2018. “Postpartum Intrauterine Device Refusal in Delhi: Reasons Analyzed.” Journal of Obstetrics and Gynecology of India 68 (3): 208–213. https://doi.org/10.1007/s13224-015-0714-9.

Novák, Annoesjka, C. de la Loge, Linda Abetz, and Egbert A. van der Meulen. 2003. “The Combined Contraceptive Vaginal Ring, NuvaRing: An International Study of User Acceptability.” Contraception 67 (3): 187–194. https://doi.org/10.1016/s0010-7824(02)00514-0.

Pandit, Suchitra N., Anahita R. Chauhan, Manjula Anagani, Sanjeeva Reddy, Ashish Birla, and Subrat K. Ray. 2014. “Multicenter Study of Contraceptive Vaginal Ring (NuvaRing®) in Normal Daily Practice in Indian Women.” Journal of Obstetrics and Gynecology of India 64 (6): 409–416. https://doi.org/10.1007/s13224-014-0559-7.

Park, Min Hae, Thang Huu Nguyen, and Thoai Dinh Ngo. 2011. “Dynamics of IUD Use in Vietnam: Implications for Family Planning Services at Primary Health Care Level.” International Journal of Women’s Health 3 (1): 429–434. https://doi.org/10.2147/IJWH.S26620.

Peters, Anny, Willy Jansen, and Francien van Driel. 2010. “The Female Condom: The International Denial of a Strong Potential.” Reproductive Health Matters 18 (35): 119–128. https://doi.org/10.1007/s10461-008-0809-7.
Robinson, Nuriya, Mosa Moshabela, Lydia Owusu-Ansah, Chisina Kapungu, and Stacie Geller. 2016. “Barriers to Intrauterine Device Uptake in a Rural Setting in Ghana.” *Health Care for Women International* 37 (2): 197–215. https://doi.org/10.1080/07399332.2014.946511.

Rominski, Sarah D., Emmanuel SK Morhe, Ernest Maya, Abukar Manu, and Vanessa K. Dalton. 2017. “Comparing Women’s Contraceptive Preferences With Their Choices in 5 Urban Family Planning Clinics in Ghana.” *Global Health: Science and Practice* 5 (1): 65–74. https://doi.org/10.9745/GHSP-D-16-00281.

Rosenstock, Irwin M. 1974. “Historical Origins of the Health Belief Model.” *Health Education Monographs* 2 (4): 328–335. https://doi.org/10.1177/01901981740020403.

Routes2Results, PSI, FHI 360, SFH Nigeria, WCGCares. 2019a. “Understanding End-User (Women) and Healthcare Provider (HCP) Preference for the IUS Contraceptive in Nigeria and Kenya.” https://6dc13253-8668-46dc-80d3-a17a285a56f3.filesusr.com/ugd/1b0149_f13154a668134622b20946ed5074adb6.pdf.

Routes2Results, PSI, FHI 360, SFH Nigeria, WCGCares. 2019b. “Understanding the Market Potential of the IUS in Kenya and Nigeria.” https://6dc13253-8668-46dc-80d3-a17a285a56f3.filesusr.com/ugd/1b0149_f3154a668134622b20946ed5074adb6.pdf.

Roy, Malabika, Avishek Hazra, Ruth Merkatz, Marlena Plagianos, Mohcene Alami, L.N. Gaur, Kumudha Aruldas, Heather Sussman, Bruce Varjina, Regine Sitruk-Ware, and the Progesterone Vaginal Ring Study Group at Participating Centers. 2020. “Progesterone Vaginal Ring as a New Contraceptive Option for Lactating Mothers: Evidence from a Multicenter Non-Randomized Comparative Clinical Trial in India.” *Contraception* 102 (3): 159–167. https://doi.org/10.1016/j.contraception.2020.04.016.

Sahin-Hodoglugil, Nuriye Nalan, Elizabeth Montgomery, Deborah Kacanek, Neetha Morar, Sibongile Mtwwa, Buisitse Nkala, Jessica Philip, Gita Ramjee, Helen Cheng, Ariane van der Straten, and the MIRA Team. 2011. “User Experiences and Acceptability Attributes of the Diaphragm and Lubricant Gel in an HIV Prevention Trial in Southern Africa.” *AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV* 23 (8): 1026–1034. https://doi.org/10.1080/09540121.2010.543879.

Santhya, K.G., Ravi Prakash, Shireen Jejeebhoy, and Santosh Singh. 2014. “Accessing Adolescent Friendly Health Clinics in India: The Perspectives of Adolescents and Youth.” *Population Council*. https://doi.org/10.31899/pgy10.1014.

Santibenchakul, Somsook, and Unnop Jaisamrarn. 2016. “Acceptability, Tolerability, and Satisfaction of a Contraceptive Vaginal Ring (the NuvaRing) among Thai Women.” *Asian Biomedicine* 10 (3): 235–241. https://doi.org/10.5372/1905-7415.1003.485.

Scavuzzi, Adriana, Alex Sandro Rolland Souza, and Melania Maria Ramos Amorim. 2016. “Continued Compliance and Degree of Satisfaction in Nulligravida and Parous Women with Intrauterine Contraceptive Devices.” *Revista Brasileira de Ginecologia e Obstetricia: Revista Da Federacao Brasileira Das Sociedades de Ginecologia e Obstetricia* 38 (3): 132–139. https://doi.org/10.1055/s-0036-1580709.

Schuyler, Ashley C., T.B. Masawure, Jennifer A. Smit, Mags Bekinsksa, Z. Mabude, C. Ngoloyi, and Joanne E. Mantell. 2016. “Building Young Women’s Knowledge and Skills in Female Condom Use: Lessons Learned from a South African Intervention.” *Health Education Research* 31 (2): 260–272. https://doi.org/10.1093/her/cyw001.

Sedgh, Gilda, Lori S Ashford, and Rubina Hussain. 2016. “Unmet Need for Contraception in Developing Countries: Examining Women’s Reasons for Not Using a Method,” *Guttmacher Institute*. https://www.guttmacher.org/report/unmet-need-for-contraception-in-developing-countries.

Shapiro, Katharine, Anuradha Roy, Sushena Reza-Paul, Nisha Gupta, Maggie Kilbourne-Brook, and Patricia S. Coffey. 2014. “Is the SILCS Diaphragm Appropriate for Women in India?” Abstracts of Posters. *The European Journal of Contraception and Reproductive Health Care* 19 (Suppl. 1): S91–S240. https://doi.org/10.3109/13625287.2014.894779.11.

Shapiro, Katharine. 2016. “Assessing Opportunities and Challenges for Potential Introduction of the SILCS Diaphragm in India.” *PATH*. https://path.azuredge.net/media/documents/DT_silcs_rpt_india.pdf.

Shapley-Quinn, Mary Kate, Kgaihlisho N. Manenzhe, Kwango Agot, Alexandra M. Minnis, Ariane van der Straten, and on bhealf of the TRIO study team. 2019. “‘We Are Not the Same’: African Women’s View of Multipurpose Prevention Products in the TRIO Clinical Study.” *International Journal of Women’s Health* 11: 97–107. https://doi.org/10.2147/IJWH.S185712.

Sharma, Megha, Shubham Joshi, Oby Nagar, and Akash Sharma. 2014. “Determinants of Intrauterine Contraceptive Device Discontinuation among Indian Women.” *Journal of Obstetrics and Gynecology of India* 64 (3): 208–211. https://doi.org/10.1007/s13224-014-0516-5.
Todd, Catherine S., Heidi E. Jones, Tracy C. Garber, Hoviyeh Afni-Holmes, Helen Woolgar, Linda-Gail Bekker, and Landon Myer. 2012. “Awareness and Interest in Intrauterine Contraceptive Device Use among HIV-Positive Women in Cape Town, South Africa.” Infectious Diseases in Obstetrics and Gynecology 2012. https://doi.org/10.1155/2012/956145.

UNFPA. 2020. “UNFPA Prequalified TCu380A IUD Manufacturers.” UNFPA. https://www.unfpaprocurement.org/documents/10157/37547/UNFPA_Prequalified+IUD+factories.pdf/49bblb03-ed69-4854-88c1-f5522f2341a8.

UNFPA. 2021. “UNFPA Product Catalog.” UNFPA. https://www.unfpa PROCUREMENT.org/products.

US FDA. 2019. “Paragard Full Prescribing Information.” US FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018680s069s070lbl.pdf.

UNFPA. 2020. “UNFPAPrequalifiedTCu380AIUDManufacturers.”UNFPA.https://www.unfpaprocurement.org/documents/10157/37547/UNFPA_Prequalified+IUD+factories.pdf/49bblb03-ed69-4854-88c1-f5522f2341a8.

Van Der Straten, Ariane, Kawango Agot, Khatija Ahmed, Rachel Weinrib, Erica N. Browne, Kghalisho Manenzhe, Fredrick Owino, Jill Schwartz, Alexandra Minnis, TRIO Study Team. 2018. “The Tablets, Ring, Injections as Options (TRIO) Study: What Young African Women Chose and Used for Future HIV and Pregnancy Prevention.” Journal of the International AIDS Society 21 (3). https://doi.org/10.1002/jia2.25094.

Van Der Westhuizen, Nadia, and Gerhard Hanekom. 2016. “Patient Knowledge about and Intention to Use the Intrauterine Contraceptive Device (IUCD) at a Tertiary-Level Hospital.” South African Journal of Obstetrics and Gynaecology 22 (2): 42–46. https://doi.org/10.7196/SAJOG.2016.v22i2.1048.

Vakilian, Katayoon, Sajedeh Molavi, Ahmad Reza Zamani, and Masoumeh Goodarzi. 2018. “Effect of Motivational Interviewing on Using Intrauterine Device in Women at High Risk for Pregnancy.” Open Access Macedonian Journal of Medical Sciences 6 (7): 1305–1309. https://doi.org/10.3889/oamjms.2018.166.

Vanyenze, Rhoda K., Lynn Atuyambe, Vista Kibirige, Sarah Mbabazi, Nazarius M. Tumwesigye, Kara Djurhuus, and Alice Nakame. 2011. “The New Female Condom (FC2) in Uganda: Perceptions and Experiences of Users and Their Sexual Partners.” African Journal of AIDS Research 10 (3): 219–224. https://doi.org/10.2989/16085906.2011.626289.

Wang, Xianmi, Meng Liu, and Yimin Cheng. 2015. “Awareness of Female Condoms and Failures Reported with Two Different Types in China.” International Journal of Gynaecology and Obstetrics 129 (2): 152–156. https://doi.org/10.1016/j.ijigo.2014.08.017.

Wasim, Tayyiba, Shysta Shaukat, Lubna Javed, and Saima Mukhtar. 2018. “Outcome of Immediate Postpartum Insertion of Intrauterine Contraceptive Device: Experience at Tertiary Care Hospital.” Journal of the Pakistan Medical Association 68 (4): 519–525. https://doi.org/10.18203/2320-1770.jpma20170407.

Wedderburn, Maxine, Deborah Bourne, Veronica Samuels-Dixon, and Nadia Robinson. 2011. “Study of Female Sex Workers, Client Types and Risk Behavior in the Sex Work Industry in Jamaica.” Population Services International. https://www.psi.org/wp-content/uploads/2020/05/Report-Jamaica-FSW_0.pdf.
Weinrib, Rachel, Alexandra Minnis, Kawango Agot, Khatija Ahmed, Fred Owino, Kghlisho Manenzhe, Helen Cheng, Ariane van der Straten. 2018. "End-Users’ Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa." AIDS and Behavior 22: 133–145. https://doi.org/10.1007/s10461-017-1911-6.

WHO. 2014. “Ensuring Human Rights in the Provision of Contraceptive Information and Services.” World Health Organization (WHO). https://apps.who.int/iris/bitstream/handle/10665/102539/9789241506748_eng.pdf?sequence=1.

WHO, UNFPA, UNAIDS, and FHI360. 2011. “The TCu380A Intrauterine Contraceptive Device (IUD): Specification, Prequalification and Guidelines for Procurement, 2010.”WHO, UNFPA, UNAIDS, and FHI360. https://www.unfpa.org/sites/default/files/resource-pdf/IUDbook_finalwlinks_042911.pdf.

Wu, Junqing, Junguo Zhang, Yuyan Li, Jinming Yang, Ying Zhou, Yiran Li, Shuangfei Xu, and Rui Zhao. 2019. "Short-Term Acceptability of the Woman’s Condom and Influencing Factors among Internal Migrants in China." BMC Public Health 19 (1410). https://doi.org/10.1186/s12889-019-7625-0.

Zafar, Zonobia, Hammad Habib, Adrienne Kols, Fauzia Assad, Enriquito R. Lu, and Anne Schuster. 2019. “Reinvigorating Postpartum Intrauterine Contraceptive Device Use in Pakistan: An Observational Assessment of Competency-Based Training of Health Providers Using Low-Cost Simulation Models.” BMC Medical Education 19 (261). https://doi.org/10.1186/s12909-019-1683-y.

Zhao, Shuping, Jihong Deng, Yan Wang, Shiliang Bi, Xiaoye Wang, Wen Qin, Zirong Huang, Li Li, Xin Mi, Liping Han, Qing Chang, and Jian Li. 2014. “Experience and Levels of Satisfaction with the Levonorgestrel-Releasing Intrauterine System in China: A Prospective Multicenter Survey.” Patient Preference and Adherence 8: 1449–1455. https://doi.org/10.2147/PPA.S68299.

Zhou, Chu, Evelyn Hsieh, Keming Rou, Jonas Tillman, Wei Dong, Xian-xiang Feng, Yan-zhen Yang, Yu-jun Yang, Xian-guo Sun, Hai-jian Zang, Ying-zhen Wu, and Zunyou Wu. 2019. "Short-Term Acceptability of Female Condom Use among Low-Fee Female Sex Workers in China: A Follow-Up Study." BMC Women’s Health 19 (77). https://doi.org/10.1186/s12905-019-0773-7.

ACKNOWLEDGMENTS

This manuscript is made possible by the generous support of the American people through the United States Agency for International Development (USAID), cooperative agreement #No. AID-OAA-A-13-00088. The contents of this paper are the sole responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government.